

FILE 'HOME' ENTERED AT 18:39:12 ON 19 MAR 2003

=> index bioscince meeetings patents
'BIOSCINCE' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
'MEEETINGS' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):meetings

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 18:40:53 ON 19 MAR 2003

93 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (stress and hypotonic) and (cell (w) culture?) and (expression or production) and
(increas or enhace)
) IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (stress and hypotonic) and (cell (w) culture?) and (expression or production) and
(increase? or enhance?)
2 FILE BIOSIS
9 FILES SEARCHED...
4 FILE BIOTECHNO
12 FILES SEARCHED...
10 FILE CANCERLIT
14 FILES SEARCHED...
4 FILE CAPLUS
24 FILES SEARCHED...
10 FILE EMBASE
3 FILE ESBIOBASE
33 FILES SEARCHED...
44 FILES SEARCHED...
15 FILE MEDLINE
2 FILE PASCAL
51 FILES SEARCHED...
1 FILE PROMT
2 FILE SCISEARCH
4 FILE TOXCENTER
59 FILES SEARCHED...
247 FILE USPATFULL
6 FILE USPAT2
64 FILES SEARCHED...
68 FILES SEARCHED...
23 FILE EUROPATFULL
82 FILES SEARCHED...
213 FILE PCTFULL
89 FILES SEARCHED...

15 FILES HAVE ONE OR MORE ANSWERS, 93 FILES SEARCHED IN STNINDEX

L1 QUE (STRESS AND HYPOTONIC) AND (CELL (W) CULTURE?) AND (EXPRESSION OR PRODUCTION) AND (INCREASE? OR ENHANCE?)

=> file hits

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.70	8.33

FILE 'USPATFULL' ENTERED AT 18:49:30 ON 19 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 Univentio

FILE 'EUROPATFULL' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 18:49:30 ON 19 MAR 2003

FILE 'CANCERLIT' ENTERED AT 18:49:30 ON 19 MAR 2003

FILE 'EMBASE' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'USPAT2' ENTERED AT 18:49:30 ON 19 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 18:49:30 ON 19 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 ACS

FILE 'ESBIOBASE' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'PASCAL' ENTERED AT 18:49:30 ON 19 MAR 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PROMT' ENTERED AT 18:49:30 ON 19 MAR 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

=> s 11
L2 247 FILE USPATFULL
L3 213 FILE PCTFULL
L4 23 FILE EUROPATFULL
L5 15 FILE MEDLINE
L6 10 FILE CANCERLIT
L7 10 FILE EMBASE
L8 6 FILE USPAT2
L9 4 FILE BIOTECHNO
L10 4 FILE CAPLUS
L11 4 FILE TOXCENTER
L12 3 FILE ESBIOBASE
L13 2 FILE BIOSIS

L14 2 FILE PASCAL
L15 2 FILE SCISEARCH
L16 1 FILE PROMT

TOTAL FOR ALL FILES
L17 546 L1

=> s 117 and (solute (s) stress)
L18 1 FILE USPATFULL
L19 2 FILE PCTFULL
L20 0 FILE EUROPATFULL
L21 0 FILE MEDLINE
L22 0 FILE CANCERLIT
L23 0 FILE EMBASE
L24 0 FILE USPAT2
L25 0 FILE BIOTECHNO
L26 0 FILE CAPLUS
L27 0 FILE TOXCENTER
L28 0 FILE ESBIOBASE
L29 0 FILE BIOSIS
L30 0 FILE PASCAL
L31 0 FILE SCISEARCH
L32 0 FILE PROMT

TOTAL FOR ALL FILES
L33 3 L17 AND (SOLUTE (S) STRESS)

=> s 117 and (mammalian (s) cell (w) culture)
L34 37 FILE USPATFULL
L35 39 FILE PCTFULL
L36 3 FILE EUROPATFULL
L37 0 FILE MEDLINE
L38 0 FILE CANCERLIT
L39 0 FILE EMBASE
L40 0 FILE USPAT2
L41 0 FILE BIOTECHNO
L42 0 FILE CAPLUS
L43 0 FILE TOXCENTER
L44 0 FILE ESBIOBASE
L45 0 FILE BIOSIS
L46 0 FILE PASCAL
L47 0 FILE SCISEARCH
L48 0 FILE PROMT

TOTAL FOR ALL FILES
L49 79 L17 AND (MAMMALIAN (S) CELL (W) CULTURE)

=> dup rem 149
PROCESSING COMPLETED FOR L49
L50 79 DUP REM L49 (0 DUPLICATES REMOVED)

=> d 150 1-79 ibib abs

L50 ANSWER 1 OF 79 USPATFULL
ACCESSION NUMBER: 2003:10680 USPATFULL
TITLE: Methods for treating patients with adenoviral vectors
INVENTOR(S): Zhang, Shuyuan, Sugar Land, TX, UNITED STATES
Thwin, Capucine, Spring, TX, UNITED STATES
Wu, Zheng, Sugar Land, TX, UNITED STATES
Cho, Toohyon, Houston, TX, UNITED STATES
PATENT ASSIGNEE(S): Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003008375	A1	20030109

APPLICATION INFO.: US 2001-33491 A1 20011227 (10)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-556570, filed on 24
 Apr 2000, PENDING Continuation of Ser. No. US
 1997-975519, filed on 20 Nov 1997, GRANTED, Pat. No. US
 6194191

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31329P	19961120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357	
NUMBER OF CLAIMS:	69	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	42 Drawing Page(s)	
LINE COUNT:	3730	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention addresses the need to improve the yields of viral vectors when grown in **cell culture** systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached **cell culture** system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 **production** with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the **increase** of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 2 OF 79 USPATFULL
 ACCESSION NUMBER: 2003:3462 USPATFULL
 TITLE: Identification of gene sequences and gene products and their specific function and relationship to pathologies in a mammal
 INVENTOR(S): Jendoubi, Moncef, Bethesda, MD, UNITED STATES
 PATENT ASSIGNEE(S): Milagen, Inc., Richmond, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003003497	A1	20030102
APPLICATION INFO.:	US 2002-213183	A1	20020805 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-906487, filed on 5 Aug 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3352		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes a basic method for discovering the function of gene and their corresponding gene products relative to a specific biological process or physiological condition. The invention provides the ability to develop therapeutic and diagnostic agents using the information obtained from the practice of the basic method. In the method, the gene product of a selected polynucleotide is delivered to a mammal to provide an immune response. The polynucleotide sequences may express, *in vivo* by immunization of an animal, or in bacterial system or other known system for **expression** of a polynucleotide sequence. The sera resulting from immunization with the gene product

contains antibodies to the gene product which are used in function determinative assays to determine the function of the gene sequence gene product relative to a biological process or physiological condition, typically a disease in a human. The information derived from the function determinative assay enables the discovery of novel genes and gene products and provides the ability to design and/or manufacture of therapeutic or diagnostic products based on the practice of the basic methodology of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 3 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2003012441 PCTFULL ED 20030228 EW 200307
TITLE (ENGLISH): METHOD FOR DETECTING MODULATORS OF NOTCH SIGNALLING
TITLE (FRENCH): PROCEDE DE DETECTION DE MODULATEURS DE SIGNALISATION DE
NOTCH
INVENTOR(S): BODMER, Mark, William, Lorantis Limited, 307 Cambridge
Science Park, Milton Road, Cambridge CB4 0WG, GB [GB,
GB];
BRIEND, Emmanuel, Cyrille, Pascale, Lorantis Limited,
307 Cambridge Science Park, Milton Road, Cambridge CB4
0WG, GB [FR, GB];
CHAMPION, Brian, Robert, Lorantis Limited, 307
Cambridge Science Park, Milton Road, Cambridge CB4 0WG,
GB [GB, GB];
MCKENZIE, Grahame, James, Lorantis Limited, 307
Cambridge Science Park, Milton Road, Cambridge CB4 0WG,
GB [GB, GB];
TUGAL, Tamara, Lorantis Limited, 307 Cambridge Science
Park, Milton Road, Cambridge CB4 0WG, GB [SK, GB];
WARD, George, Albert, Lorantis Limited, 307 Cambridge
Science Park, Milton Road, Cambridge CB4 0WG, GB [GB,
GB];
YOUNG, Lesley, Lynn, Lorantis Limited, 307 Cambridge
Science Park, Milton Road, Cambridge CB4 0WG, GB [GB,
GB]
PATENT ASSIGNEE(S): LORANTIS LIMITED, 307 Cambridge Science Park, Milton
Road, Cambridge CB4 0WG, GB [GB, GB], for all
designates States except US;
BODMER, Mark, William, Lorantis Limited, 307 Cambridge
Science Park, Milton Road, Cambridge CB4 0WG, GB [GB,
GB], for US only;
BRIEND, Emmanuel, Cyrille, Pascale, Lorantis Limited,
307 Cambridge Science Park, Milton Road, Cambridge CB4
0WG, GB [FR, GB], for US only;
CHAMPION, Brian, Robert, Lorantis Limited, 307
Cambridge Science Park, Milton Road, Cambridge CB4 0WG,
GB [GB, GB], for US only;
MCKENZIE, Grahame, James, Lorantis Limited, 307
Cambridge Science Park, Milton Road, Cambridge CB4 0WG,
GB [GB, GB], for US only;
TUGAL, Tamara, Lorantis Limited, 307 Cambridge Science
Park, Milton Road, Cambridge CB4 0WG, GB [SK, GB], for
US only;
WARD, George, Albert, Lorantis Limited, 307 Cambridge
Science Park, Milton Road, Cambridge CB4 0WG, GB [GB,
GB], for US only;
YOUNG, Lesley, Lynn, Lorantis Limited, 307 Cambridge
Science Park, Milton Road, Cambridge CB4 0WG, GB [GB,
GB], for US only
AGENT: MALLALIEU, Catherine, Louise\$, D. Young & Co., 21 New
Fetter Lane, London EC4A 1DA\$, GB
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003012441	A1	20030213

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (ARIPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EAPO):

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC
 NL PT SE SK TR

RW (EPO):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-GB3397 A 20020725

PRIORITY INFO.:

GB 2001-0118153.6 20010725

GB 2002-0207930.9 20020405

GB 2002-0212282.8 20020528

GB 2002-0212283.6 20020528

ABEN A method for detecting modulators of Notch signalling is described. The method comprises the step of monitoring Notch signalling in a cell of the immune system in the presence of a candidate modulator.

ABFR L'invention concerne un procede de detection de modulateurs de signalisation de Notch. Ce procede comprend l'etape consistant a controler la signalisation de Notch dans une cellule du systeme immunitaire en presence d'un modulateur candidat.

L50 ANSWER 4 OF 79

PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER:

2003011317 PCTFULL ED 20030228 EW 200307

TITLE (ENGLISH):

MODULATORS OF NOTCH SIGNALLING FOR USE IN IMMUNOTHERAPY

TITLE (FRENCH):

MODULATEURS DE SIGNALISATION DE NOTCH UTILISES EN

IMMUNOTHERAPIE

INVENTOR(S):

BODMER, Mark, William, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB];

BRIEND, Emmanuel, Cyrille, Pascal, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [FR, GB];

CHAMPION, Brian, Robert, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB];

YOUNG, Lesley, Lynn, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB]

PATENT ASSIGNEE(S):

LORANTIS LIMITED, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB], for all designates States except US;

BODMER, Mark, William, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB], for US only;

BRIEND, Emmanuel, Cyrille, Pascal, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [FR, GB], for US only;

CHAMPION, Brian, Robert, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB], for US only;

YOUNG, Lesley, Lynn, Lorantis Limited, 307 Cambridge Science Park, Milton Road, Cambridge CB4 0WG, GB [GB, GB], for US only

AGENT:

MALLALIEU, Catherine, Louise\$, D Young & Co., 21 New Fetter Lane, London EC4A 1DA\$, GB

LANGUAGE OF FILING:

English

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES W:	WO 2003011317	A1	20030213
RW (ARIPO):	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-GB3426	A	20020725
PRIORITY INFO.:	GB 2001-0118153.6		20010725
	GB 2002-0207930.9		20020405
	GB 2002-0212282.8		20020528
	GB 2002-0212283.6		20020528
ABEN	The present invention provides new uses of modulators of Notch signalling in therapy and corresponding methods of treatment.		
ABFR	La presente invention concerne de nouvelles utilisations de modulateurs de signalisation de Notch en therapie, et des procedes de traitement correspondants.		

L50 ANSWER 5 OF 79 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER:	1281404 EUROPATFULL EW 200306 FS OS		
TITLE:	Use of antibodies against the urokinase receptor. Antikoerper gegen den Urokinaserezeptor und ihre Verwendung. Anticorps contre le recepteur de l'urokinase et leur utilisation.		
INVENTOR(S):	Bruenner, Nils, Thranevaenget 8, 2.th, 2900 Hellerup, DK; Pyke, Charles, Solbakken 4, 3400 Hilleroed, DK; Roenne, Ebbe, Lundevej 71, 4400 Kalundborg, DK; Hooyer-Hansen, Gunilla, Toftekaersvej 67, 2820 Gentofte, DK; Danoe, Keld, L.E. Bruunsvej 20, 2920 Charlottenlund, DK; Ellis, Vincent, 18 Cavendish Avenue, Woodford Green, Essex IG8 9DA, GB; Behrendt, Niels, Elsevej 62, 3500 Vaerloese, DK		
PATENT ASSIGNEE(S):	Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning), c/o attorney Michael Rostock Vester Voldgade 90, DK-1552 Copenhagen V, DK		
PATENT ASSIGNEE NO:	1295820		
AGENT:	Plougmann & Vingtoft A/S, Sundkrogsgade 9, P.O. Box 831, 2100 Copenhagen O, DK		
AGENT NUMBER:	101171		
OTHER SOURCE:	MEPA2003012 EP 1281404 A2 0114		
SOURCE:	Wila-EPZ-2003-H06-T1b		
DOCUMENT TYPE:	Patent		
LANGUAGE:	Anmeldung in Englisch; Veroeffentlichung in Englisch		
DESIGNATED STATES:	R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R IT; R LI; R LU; R NL; R SE		
PATENT INFO.PUB.TYPE:	EPA2 EUROPÄISCHE PATENTANMELDUNG		
PATENT INFORMATION:	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 1281404	A2	20030205
			20030205

APPLICATION INFO.: EP 2002-13976 19911018
PRIORITY APPLN. INFO.: WO 1990-DK270 19901018
RELATED DOC. INFO.: EP 574391 DIV

L50 ANSWER 6 OF 79 USPATFULL
ACCESSION NUMBER: 2002:337274 USPATFULL
TITLE: Method and devices for the removal of psoralens from blood products
INVENTOR(S): Hei, Derek J., Madison, WI, UNITED STATES
Cimino, George D., Lafayette, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002192632	A1	20021219
APPLICATION INFO.:	US 2002-51976	A1	20020116 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-537962, filed on 28 Mar 2000, ABANDONED Continuation of Ser. No. US 1996-660910, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1995-484926, filed on 7 Jun 1995, ABANDONED		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 63 Drawing Page(s)
LINE COUNT: 8018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method of treating product which contains a nucleic acid-containing pathogen to be inactivated. One such method involves forming a mixture comprising a blood product, free psoralen, and low molecular weight products, and contacting the mixture with a hypercrosslinked resin to remove at least substantially all of the free psoralen and the low molecular weight psoralen photoproducts. A hypercrosslinked resin in this method preferably eliminates a wetting step that a number of other types of resins require before being used to absorb the pathogen inactivating compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 7 OF 79 USPATFULL
ACCESSION NUMBER: 2002:322559 USPATFULL
TITLE: AN IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
INVENTOR(S): Zhang, Shuyuan, Sugar Land, TX, UNITED STATES
Thwin, Capucine, Spring, TX, UNITED STATES
Wu, Zheng, Sugar Land, TX, UNITED STATES
Cho, Toohyon, UNITED STATES
Gallagher, Shawn, Missouri City, TX, UNITED STATES
PATENT ASSIGNEE(S): Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002182723	A1	20021205
APPLICATION INFO.:	US 2001-880609	A1	20010612 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-203078, filed on 1 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1997-975519, filed on 20 Nov 1997, GRANTED, Pat. No. US 6194191		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31329P	19961120 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P.,
Suite 2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 49 Drawing Page(s)
LINE COUNT: 6000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention addresses the need to improve the yields of viral vectors when grown in **cell culture** systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached **cell culture** system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 **production** with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the **increase** of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 8 OF 79 USPATFULL
ACCESSION NUMBER: 2002:314738 USPATFULL
TITLE: Methods for producing purified adenoviral vectors
INVENTOR(S):
Zhang, Shuyuan, Sugarland, TX, UNITED STATES
Thwin, Capucine, Spring, TX, UNITED STATES
Wu, Zheng, Sugarland, TX, UNITED STATES
Cho, Toohyon, Houston, TX, UNITED STATES
PATENT ASSIGNEE(S): Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177215	A1	20021128
APPLICATION INFO.:	US 2001-33571	A1	20011227 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-556570, filed on 24 Apr 2000, PENDING Continuation of Ser. No. US 1997-975519, filed on 20 Nov 1997, GRANTED, Pat. No. US 6194191		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31329P	19961120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357	
NUMBER OF CLAIMS:	69	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Page(s)	
LINE COUNT:	3720	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention addresses the need to improve the yields of viral vectors when grown in **cell culture** systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached **cell culture** system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 **production** with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the **increase** of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 9 OF 79 USPATFULL

ACCESSION NUMBER: 2002:289245 USPATFULL
TITLE: Methods and compositions for RNA interference
INVENTOR(S): Beach, David, Boston, MA, UNITED STATES
Bernstein, Emily, Huntington, NY, UNITED STATES
Caudy, Amy, Melville, NY, UNITED STATES
Hammond, Scott, Huntington, NY, UNITED STATES
Hannon, Gregory, Huntington, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002162126	A1	20021031
APPLICATION INFO.:	US 2001-866557	A1	20010524 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US8435, filed on 16 Mar 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-189739P	20000316 (60)
	US 2000-243097P	20001024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	2194	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the "target" gene).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 10 OF 79 USPATFULL

ACCESSION NUMBER: 2002:287647 USPATFULL
TITLE: Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
INVENTOR(S): Hariri, Robert J., Florham Park, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160510	A1	20021031
APPLICATION INFO.:	US 2002-74976	A1	20020213 (10)
PRIORITY INFORMATION:	US 2001-268560P	20010214 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	CRAIG G. COCHENOUR, BUCHANAN INGERSOLL, P.C., ONE OXFORD CENTRE, 20th FLOOR, 301 GRANT STREET, PITTSBURGH, PA, 15219		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		
LINE COUNT:	1647		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of manufacturing a tissue matrix for implantation into a

patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 11 OF 79 USPATFULL

ACCESSION NUMBER: 2002:243142 USPATFULL

TITLE: Genes encoding several poly(ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith

INVENTOR(S): Jacobson, Myron K., Lexington, CT, UNITED STATES
Jacobson, Elaine L., Lexington, CT, UNITED STATES
Ame, Jean-Christophe, Obernai, FRANCE
Lin, Winston, Lexington, CT, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002132328 A1 20020919

APPLICATION INFO.: US 2001-973451 A1 20011009 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-302812, filed on 30 Apr 1999, GRANTED, Pat. No. US 6333148

NUMBER DATE

PRIORITY INFORMATION: US 1998-83768P 19980501 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Fulbright & Jaworski LLP, 666 Fifth Avenue, New York, NY, 10103

NUMBER OF CLAIMS: 66

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 21 Drawing Page(s)

LINE COUNT: 4300

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The isolation and characterization of cDNAs encoding poly(ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in *E. coli* results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 12 OF 79 USPATFULL

ACCESSION NUMBER: 2002:214199 USPATFULL

TITLE: Method and devices for the removal of psoralens from blood products

INVENTOR(S): Hei, Derek J., Madison, WI, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002115585 A1 20020822
APPLICATION INFO.: US 2001-872384 A1 20010601 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1996-659249, filed on 7 Jun
1996, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Charles D. Holland, Morrison & Foerster LLP, 755 Page
Mill Road, Palo Alto, CA, 94304-1018
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 70 Drawing Page(s)
LINE COUNT: 7924

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method for removing a pathogen-inactivating compound such as psoralen from a biological fluid such as blood or a blood product. One such method involves treating a blood product which contains a nucleic acid-containing pathogen to be inactivated. This method includes adding a pathogen-inactivating compound such as psoralen to the blood product; irradiating the psoralen and the blood product to form a mixture comprising the blood product, free psoralen, and low molecular weight psoralen photoproducts; and contacting the mixture with a hypercrosslinked resin to remove at least substantially all of the free psoralen and the low molecular weight psoralen photoproducts. A hypercrosslinked resin in this method preferably eliminates a wetting step that a number of other types of resins require before being used to adsorb the pathogen inactivating compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 13 OF 79 USPATFULL
ACCESSION NUMBER: 2002:213828 USPATFULL
TITLE: Decellularized tissue engineered constructs and tissues
INVENTOR(S): Mitchell, Shannon, Durham, NC, UNITED STATES
Koh, Jennifer, Irvine, CA, UNITED STATES
Prabhakar, Vikas, Boston, MA, UNITED STATES
Niklason, Laura, Hillsborough, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002115208	A1	20020822
APPLICATION INFO.:	US 2001-931506	A1	20010816 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225698P	20000816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Monica R. Gerber, M.D., Ph.D., Choate, Hall & Stewart, 53 State Street, Exchange Place, Boston, MA, 02109	
NUMBER OF CLAIMS:	218	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2746	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB New methods for producing tissue engineered constructs and engineered native tissues are disclosed. The methods include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for **production** of the construct, the developing construct may be

subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. The methods also include producing an engineered native tissue by harvesting tissue from an animal or human, performing one or more tissue engineering steps on the tissue, and subjecting the tissue to decellularization. The decellularized, engineered native tissue may then be subjected to further tissue engineering steps.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 14 OF 79 USPATFULL

ACCESSION NUMBER: 2002:198588 USPATFULL
TITLE: IDENTIFICATION OF GENE SEQUENCES AND GENE PRODUCTS AND THEIR SPECIFIC FUNCTION AND RELATIONSHIP TO PATHOLOGIES IN A MAMMAL
INVENTOR(S): JENBOUBI, MONCEF, BETHESDA, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106688	A1	20020808
APPLICATION INFO.:	US 1997-906487	A1	19970805 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LYON & LYON LLP, 633 WEST FIFTH STREET, SUITE 4700, LOS ANGELES, CA, 90071		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3380		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes a basic method for discovering the function of gene and their corresponding gene products relative to a specific biological process or physiological condition. The invention provides the ability to develop therapeutic and diagnostic agents using the information obtained from the practice of the basic method. In the method, the gene product of a selected polynucleotide is delivered to a mammal to provide an immune response. The polynucleotide sequences may express, *in vivo* by immunization of an animal, or in bacterial system or other known system for **expression** of a polynucleotide sequence. The sera resulting from immunization with the gene product contains antibodies to the gene product which are used in function determinative assays to determine the function of the gene sequence gene product relative to a biological process or physiological condition, typically a disease in a human. The information derived from the function determinative assay enables the discovery of novel genes and gene products and provides the ability to design and/or manufacture of therapeutic or diagnostic products based on the practice of the basic methodology of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 15 OF 79 USPATFULL

ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102604	A1	20020801
APPLICATION INFO.:	US 2000-731872	A1	20001207 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1999-169629P 19991208 (60)
 US 2000-187470P 20000306 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., Genset Corporation, 10665
 Srento Valley Road, San Diego, CA, 92121-1609
 NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Page(s)
 LINE COUNT: 28061
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention concerns GENSET polynucleotides and polypeptides. Such
 GENSET products may be used as reagents in forensic analyses, as
 chromosome markers, as tissue/cell/organelle-specific markers, in the
 production of expression vectors. In addition, they
 may be used in screening and diagnosis assays for abnormal GENSET
 expression and/or biological activity and for screening
 compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 16 OF 79 USPATFULL
 ACCESSION NUMBER: 2002:191516 USPATFULL
 TITLE: Diagnostics and therapeutics for ocular disorders
 INVENTOR(S): Hageman, Gregory S., Coralville, IA, UNITED STATES
 Mullins, Robert F., Coralville, IA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102581	A1	20020801
APPLICATION INFO.:	US 2001-949261	A1	20010906 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-510230, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2001-845745, filed on 30 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-120822P	19990219 (60)
	US 1999-120668P	19990219 (60)
	US 1999-123052P	19990305 (60)
	US 2000-200698P	20000429 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	5644	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to methods for treating, preventing and diagnosing drusen-associated disorders.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 17 OF 79 USPATFULL
 ACCESSION NUMBER: 2002:165215 USPATFULL
 TITLE: Methods and reagents to regulate apoptosis
 INVENTOR(S): Syken, Joshua, Jamaica Plain, MA, UNITED STATES
 Munger, Karl, Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086844	A1	20020704
APPLICATION INFO.:	US 2001-908992	A1	20010719 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219718P	20000719 (60)
	US 2000-219537P	20000720 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	3843	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids and vectors encoding two splice forms of Tid1 (Tid-1L and Tid-1S) and cells and non-human organisms comprising such. The invention further provides methods for modulating apoptosis in a cell by modulating the amount and/or activity of these two splice forms relative to each other. Such methods can be used in vivo and in vitro, e.g., in **cell cultures**, for either making cells more susceptible to apoptosis or more resistant to it.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 18 OF 79 USPATFULL
 ACCESSION NUMBER: 2002:105937 USPATFULL
 TITLE: Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies
 INVENTOR(S): Ruben, Steven A., Olney, MD, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055142	A1	20020509
APPLICATION INFO.:	US 2001-862419	A1	20010523 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US31919, filed on 21 Nov 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-167247P	19991124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	11747	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to novel human MIP-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human MIP-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human MIP-like polypeptides.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 19 OF 79 USPATFULL
 ACCESSION NUMBER: 2002:66639 USPATFULL
 TITLE: Compositions comprising heat shock proteins or alpha(2)

INVENTOR(S):

macroglobulin, antigenic molecules and saponins, and
methods of use thereof
Armen, Garo H., Manhasset, NY, UNITED STATES

PATENT INFORMATION:
APPLICATION INFO.:

NUMBER	KIND	DATE
US 2002037290	A1	20020328
US 2001-909778	A1	20010720 (9)

PRIORITY INFORMATION:

US 2000-223133P 20000807 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

Pennie & Edmonds LLP, 1155 Avenue of the Americas, New
York, NY, 10036-2711

NUMBER OF CLAIMS:

119

EXEMPLARY CLAIM:

1

LINE COUNT:

4136

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (.alpha.2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsp's that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp 170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or .alpha.2M, free in solution, and/or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or .alpha.2M-antigenic molecule complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 20 OF 79 USPATFULL

ACCESSION NUMBER:

2002:48016 USPATFULL

TITLE:

Complexes of alpha (2) macroglobulin and antigenic
molecules for immunotherapy

INVENTOR(S):

Srivastava, Pramod K., Avon, CT, UNITED STATES

PATENT INFORMATION:

NUMBER	KIND	DATE
US 2002028207	A1	20020307
US 2001-873403	A1	20010604 (9)

APPLICATION INFO.:

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-625139, filed
on 25 Jul 2000, PENDING

PRIORITY INFORMATION:

US 2000-209266P 20000602 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW
YORK, NY, 100362711

NUMBER OF CLAIMS:

36

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

65 Drawing Page(s)

LINE COUNT:

4477

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 21 OF 79 USPATFULL

ACCESSION NUMBER: 2002:27153 USPATFULL
TITLE: Methods for reducing adventitious agents and toxins and **cell culture** reagents produced thereby
INVENTOR(S): Biddle, William C., Buffalo, NY, UNITED STATES
Fike, Richard M., Clarence, NY, UNITED STATES
Dadey, Barbara M., East Aurora, NY, UNITED STATES
Bulera, Thomas E., Lancaster, NY, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002015999 A1 20020207

APPLICATION INFO.: US 2000-576900 A1 20000523 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-343686, filed on 30 Jun 1999, ABANDONED

NUMBER DATE

PRIORITY INFORMATION: US 1998-91275P 19980630 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 25 Drawing Page(s)

LINE COUNT: 2703

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to a method to reduce, substantially reduce, inactivate or eliminate adventitious agents and/or toxins in a sample, particularly in nutritive media, media supplements, media subgroups and buffer formulations. Specifically, the present invention provides powdered nutritive media, media supplements and media subgroups produced by the methods of the invention, particularly **cell culture** media supplements (including powdered sera such as powdered fetal bovine serum (FBS)). The invention further provides powdered buffer formulations produced by the methods of the invention. The invention also provides kits and methods for cultivation of prokaryotic and eukaryotic cells, particularly bacterial cells, yeast cells, plant cells and animal cells (including human cells) using these nutritive media, media supplements, media subgroups and buffer formulations. The invention also relates to methods for producing storage stable cells having reduced, substantially reduced or eliminated adventitious agents or toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 22 OF 79 USPATFULL

ACCESSION NUMBER: 2002:317295 USPATFULL
TITLE: Cell proliferation related genes
INVENTOR(S): Zervos, Antonis S., Woburn, MA, United States
PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6489136 B1 20021203
APPLICATION INFO.: US 1998-75460 19980508 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46077P	19970509 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Bugalsky, Gabrielle	
LEGAL REPRESENTATIVE:	Fish & Richardson PC	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	4907	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to three novel cancer related genes, Nmi, Omi and Rim. The Nmi gene encodes a myc gene product-binding protein. The Omi gene encodes a mammalian serine protease protein comprising an amino terminal regulatory domain, which includes a signal peptidase site, a triple repeat motif, an SH3 binding domain, and a consensus Mxi2/p38 kinase phosphorylation site, and a carboxy terminus serine protease catalytic domain. The retinoblastoma-interacting myosin-like gene (Rim gene) encodes a retinoblastoma binding protein comprising two leucine zipper structures, an RB family binding motif, an E1A/CtBP binding motif, and four nuclear localization sequences. Described herein are isolated and antisense nucleic acids molecules, recombinant **expression** vectors, host cells and non-human transgenic animals containing an insertion or a disruption of the Nmi, Omi and Rim genes. Diagnostic, screening and therapeutic methods utilizing the compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 23 OF 79 USPATFULL
ACCESSION NUMBER: 2002:122485 USPATFULL
TITLE: Genes encoding several poly(ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith
INVENTOR(S): Jacobson, Myron K., Lexington, KY, United States
Jacobson, Elaine L., Lexington, KY, United States
Ame, Jean-Christophe, Obernai, FRANCE
Lin, Winston, Lexington, KY, United States
PATENT ASSIGNEE(S): University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6395543	B1	20020528
APPLICATION INFO.:	US 2000-511507		20000223 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-302812, filed on 30 Apr 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83768P	19980501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Brusca, John S.	
ASSISTANT EXAMINER:	Lacourciere, Karen A	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski, LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	2495	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The isolation and characterization of cDNAs encoding poly(ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in *E. coli* results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 24 OF 79 USPATFULL

ACCESSION NUMBER: 2002:5881 USPATFULL
TITLE: Genes encoding several poly (ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith
INVENTOR(S): Jacobson, Myron K., Lexington, KY, United States
Jacobson, Elaine L., Lexington, KY, United States
Ame , Jean-Christophe, Obernai, FRANCE
Lin, Winston, Lexington, KY, United States
PATENT ASSIGNEE(S): University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6337202	B1	20020108
APPLICATION INFO.:	US 2000-511477		20000223 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-302812, filed on 30 Apr 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83768P	19980501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Brusca, John S.	
ASSISTANT EXAMINER:	Lacourciere, Karen A.	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski, LLP	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	2969	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The isolation and characterization of cDNAs encoding poly(ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in *E. coli* results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense

oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 25 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002096923 PCTFULL ED 20021217 EW 200249
TITLE (ENGLISH): PLANT ARTIFICIAL CHROMOSOMES, USES THEREOF AND METHODS
OF PREPARING PLANT ARTIFICIAL CHROMOSOMES
TITLE (FRENCH): CHROMOSOMES ARTIFICIELS DE PLANTES, UTILISATION DE CES
DERNIERS ET PROCEDES DE PREPARATION DE CHROMOSOMES
ARTIFICIELS DE PLANTES
INVENTOR(S): PEREZ, Carl, 1201-7680 Granville Avenue, Richmond, B.C.
V6Y 4B9, CA [US, CA];
FABIJANSKI, Steven, F., 6068 Forestglen Crescent,
Ottawa, Ontario K1C 5N4, CA [US, CA];
PERKINS, Edward, 7610 Lawrence Drive, Burnaby, B.C. V5A
1T6, CA [US, CA]
PATENT ASSIGNEE(S): CHROMOS MOLECULAR SYSTEMS, INC., 8081 Lougheed Highway,
Burnaby, BC V5A 1W9, CA [CA, CA], for all designates
States except US;
AGRISOMA, INC., 8081 Lougheed Highway, Burnaby, B.C.
V5A 1W9, CA [CA, CA], for all designates States except
US;
PEREZ, Carl, 1201-7680 Granville Avenue, Richmond, B.C.
V6Y 4B9, CA [US, CA], for US only;
FABIJANSKI, Steven, F., 6068 Forestglen Crescent,
Ottawa, Ontario K1C 5N4, CA [US, CA], for US only;
PERKINS, Edward, 7610 Lawrence Drive, Burnaby, B.C. V5A
1T6, CA [US, CA], for US only
AGENT: SEIDMAN, Stephanie, L.\$, Heller Ehrman White &
McAuliffe LLP, 4250 La Jolla Village Square, 7th floor,
La Jolla, CA 9122-1246\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2002096923 A1 20021205
DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (ARIPO): AM AZ BY KG KZ MD RU TJ TM
RW (EAPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US17451 A 20020530
PRIORITY INFO.: US 2001-60/294,687 20010530
US 2001-60/296,329 20010604
ABEN Methods for preparing cell lines that contain plant artificial
chromosomes, methods for preparation of plant artificial chromosomes,
methods for targeted insertion of heterologous DNA into plant artificial
chromosomes, and methods for delivery of plant chromosomes to selected
cells and tissues are provided. In particular, plant artificial
chromosomes that are substantially composed of repeated nucleic acid
units of varying amounts of heterochromatin and euchromatin are
provided. Also provided are methods of using plant and animal artificial

chromosomes in the **production** of valuable transgenic plants. Methods for identifying plant genes encoding particular traits using artificial chromosomes and for producing an acrocentric plant chromosome are also provided.

ABFR L'invention concerne des lignees cellulaires qui contiennent des chromosomes artificiels de plantes. L'invention a aussi pour objet des procedes de preparation de chromosomes artificiels de plantes, des procedes pour l'insertion ciblee d'ADN heterologue dans des chromosomes artificiels de plantes, et des procedes pour administrer des chromosomes de plantes a des cellules et des tissus selectionnes. En particulier, l'invention traite de chromosomes artificiels de plantes qui sont sensiblement composees d'unites d'acide nucleique repetees de quantites diverses d'heterochromatine et d'euchromatine. Enfin, l'invention a aussi pour objet des procedes d'utilisation de chromosomes artificiels de plantes et d'animaux dans la **production** de plantes transgeniques interessantes. L'invention concerne enfin des procedes permettant d'identifier des genes de plantes codant des caracteristiques particulières a l'aide de chromosomes artificiels et de produire un chromosome de plante acrocentrique.

L50 ANSWER 26 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002083898 PCTFULL ED 20021107 EW 200243
TITLE (ENGLISH): FULL-LENGTH HUMAN CDNAS ENCODING POTENTIALLY SECRETED PROTEINS
TITLE (FRENCH): ADN COMPLEMENTAIRES HUMAINS PLEINE LONGUEUR CODANT DES PROTEINES POTENTIELLEMENT SECRETEES
INVENTOR(S): BEJANIN, Stephane, 35, bd de Rochechouart, F-75009 Paris, FR [FR, FR]; TANAKA, Hiroaki, 8, av. de la Providence, F-92160 Antony, FR [FR, FR]; DUMAS MILNE EDWARDS, Jean-Baptiste, 8, rue Gregoire de Tours, F-75006 Paris, FR [FR, FR]; JOBERT, Severin, 7, impasse Tourneux, F-75010 Paris, FR [FR, FR]; GIORDANO, Jean-Yves, 12, rue Duhesme, F-75018 Paris, FR [FR, FR]
PATENT ASSIGNEE(S): GENSET, Intellectual Property Department, 24, rue Royale, F-75008 Paris, FR [FR, FR], for all designates States except US; BEJANIN, Stephane, 35, bd de Rochechouart, F-75009 Paris, FR [FR, FR], for US only; TANAKA, Hiroaki, 8, av. de la Providence, F-92160 Antony, FR [FR, FR], for US only; DUMAS MILNE EDWARDS, Jean-Baptiste, 8, rue Gregoire de Tours, F-75006 Paris, FR [FR, FR], for US only; JOBERT, Severin, 7, impasse Tourneux, F-75010 Paris, FR [FR, FR], for US only; GIORDANO, Jean-Yves, 12, rue Duhesme, F-75018 Paris, FR [FR, FR], for US only
AGENT: GENSET\$, Intellectual Property Department, 24, rue Royale, F-75008 Paris\$, FR
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002083898	A1	20021024

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-IB914 A 20010418

ABEN The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

ABFR Cette invention a trait a des polynucleotides et a des polypeptides GENSET, lesquels peuvent etre utilises en tant que reactifs dans des analyses judiciaires, comme marqueurs chromosomiques et comme marqueurs specifiques de tissu/cellule/organite dans la production de vecteurs d'expression. Ils peuvent egalement etre utilises dans des epreuves de criblage et dans des analyses diagnostiques portant sur une expression anormale de GENSET et/ou aux fins d'une activite biologique ainsi que pour le criblage de composes pouvant servir au traitement d'etats pathologiques lies aux GENSET.

L50 ANSWER 27 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002077174 PCTFULL ED 20021011 EW 200240
TITLE (ENGLISH): HUMAN CYTOKINE RECEPTOR
TITLE (FRENCH): RECEPTEUR DE CYTOKINE HUMAINE
INVENTOR(S): PRESNELL, Scott, R., 2902 North Puget Sound Avenue, Tacoma, WA 98407, US;
XU, Wenfeng, 12432 54th Avenue W, Mukilteo, WA 98275, US;
KINDSVOGEL, Wayne, 6014 24th Avenue Northeast, Seattle, WA 98115, US;
CHEN, Zhi, 1321 Minor Avenue, Apartment B504, Seattle, WA 98101, US;
HUGHES, Steven, D., 3610 NE 65th Street, Seattle, WA 98115, US
PATENT ASSIGNEE(S): ZYMOGENETICS, INC., 1201 Eastlake Avenue East, Seattle, WA 98102, US [US, US]

AGENT: JOHNSON, Jennifer, K.S., ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102\$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 2002077174	A2	20021003

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US8811 A 20020322
PRIORITY INFO.: US 2001-60/279,222 20010327

ABEN Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as Zcytor16.

ABFR Les cytokines et leurs recepteurs ont prouve leur utilite, aussi bien dans le domaine de la recherche fondamentale que dans celui de la

therapeutique. La presente invention concerne un nouveau receiteur de la cytokine humaine, appele ≤ Zcytor16 ≥.

L50 ANSWER 28 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002074156 PCTFULL ED 20021010 EW 200239
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS
OF COLON CANCER
TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE THERAPIE ET DE DIAGNOSTIC
DU CANCER DU COLON
INVENTOR(S): JIANG, Yuqiu, 5001 S. 232nd Street, Kent, WA 98032, US
[CN, US];
CHENAULT, Ruth, A., 10500 Meridian Avenue North, Apt.
A-408, Seattle, WA 98133, US [US, US];
XU, Jiangchun, 15805 S.E. 43rd Place, Bellevue, WA
98006, US [US, US];
INDIRIAS, Carol, Yoseph, 1541 N.W. 52nd Street,
Seattle, WA 98107, US [US, US];
LODES, Michael, J., 9223 36th Avenue S.W., Seattle, WA
98126, US [US, US];
SECRIST, Heather, 3844 35th Avenue W., Seattle, WA
98199, US [US, US];
CARTER, Darrick, 321 Summit Avenue E., Seattle, WA
98102, US [US, US];
FANGER, Gary, R., 15906 29th Drive S.E., Mill Creek, WA
98012, US [US, US];
SMITH, Carole, L., 6000 17th Avenue S.W., Apt. 6,
Seattle, WA 98106, US [US, US];
DURHAM, Margarita, 3444 36th Avenue W., Seattle, WA
98199, US [US, US];
STOLK, John, A., 7436 N.E. 144th Place, Bothell, WA
98011, US [US, US]
PATENT ASSIGNEE(S): CORIXA CORPORATION, 1124 Columbia Street, Suite 200,
Seattle, WA 98104, US [US, US], for all designates
States except US;
JIANG, Yuqiu, 5001 S. 232nd Street, Kent, WA 98032, US
[CN, US], for US only;
CHENAULT, Ruth, A., 10500 Meridian Avenue North, Apt.
A-408, Seattle, WA 98133, US [US, US], for US only;
XU, Jiangchun, 15805 S.E. 43rd Place, Bellevue, WA
98006, US [US, US], for US only;
INDIRIAS, Carol, Yoseph, 1541 N.W. 52nd Street,
Seattle, WA 98107, US [US, US], for US only;
LODES, Michael, J., 9223 36th Avenue S.W., Seattle, WA
98126, US [US, US], for US only;
SECRIST, Heather, 3844 35th Avenue W., Seattle, WA
98199, US [US, US], for US only;
CARTER, Darrick, 321 Summit Avenue E., Seattle, WA
98102, US [US, US], for US only;
FANGER, Gary, R., 15906 29th Drive S.E., Mill Creek, WA
98012, US [US, US], for US only;
SMITH, Carole, L., 6000 17th Avenue S.W., Apt. 6,
Seattle, WA 98106, US [US, US], for US only;
DURHAM, Margarita, 3444 36th Avenue W., Seattle, WA
98199, US [US, US], for US only;
STOLK, John, A., 7436 N.E. 144th Place, Bothell, WA
98011, US [US, US], for US only
AGENT: CHRISTIANSEN, William, T. S., Seed Intellectual Property
Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle,
WA 98104-7092\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
 GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (ARIPO): AM AZ BY KG KZ MD RU TJ TM

RW (EAPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

RW (EPO): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US2870 A 20020201

PRIORITY INFO.: US 2001-60/267, 400 20010202
 US 2001-60/267, 382 20010207
 US 2001-60/290, 322 20010511
 US 2001-60/305, 265 20010712
 US 2001-60/313, 077 20010816

ABEN Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

ABFR L'invention concerne des compositions et des procedes de therapie et de diagnostic du cancer et en particulier du cancer du colon. Les compositions de la presente invention comportent un ou plusieurs polypeptide(s) de la tumeur du colon, des parties immunogenes de celles-ci, des polynucleotides codant ces polypeptides, une cellule de presentation d'un antigene qui exprime ces polypeptides et des lymphocytes T specifiques de ces cellules exprimant ces polypeptides. Les compositions de la presente invention servent par exemple, a diagnostiquer, prevenir et/ou traiter des maladies et en particulier le cancer du colon.

L50 ANSWER 29 OF 79 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 2002064795 PCTFULL ED 20020904 EW 200234
 TITLE (ENGLISH): ENZYMES
 TITLE (FRENCH): ENZYMES
 INVENTOR(S): SANJANWALA, Madhusudan, M., 210 Silvia Court, Los Altos, CA 94024, US [US, US];
 LU, Yan, 3885 Corrina Way, Palo Alto, CA 94303, US [CN, US];
 LEE, Ernestine, A., 624 Kains Street, Albany, CA 94706, US [US, US];
 HAFALIA, April, J., A., 2227 Calle de Primavera, Santa Clara, CA 95054, US [US, US];
 WARREN, Bridget, A., 10130 Parkwood Drive #2, Cupertino, CA 95014, US [US, US];
 BAUGHN, Mariah, R., 14244 Santiago Road, San Leandro, CA 94577, US [US, US];
 TANG, Tom, Y., 4230 Ranwick Court, San Jose, CA 95118, US [US, US];
 YUE, Henry, 826 Lois Avenue, Sunnyvale, CA 94087, US [US, US];
 YAO, Monique, G., 1189 Woodgate Drive, Carmel, IN 46033, US [US, US];
 LEE, Sally, 825 East Evelyn, #425, Sunnyvale, CA 94086, US [US, US];
 THORNTON, Michael, 9 Medway Road, Woodside, CA 94062, US [US, US];
 WALIA, Narinder, K., 890 Davis Street #205, San Leandro, CA 94577, US [US, US];

XU, Yuming, 1739 Walnut Drive, Mountain View, CA 94040,
US [US, US];
TRAN, Uyen, K., 2638 Mabury Square, San Jose, CA 95133,
US [US, US];
LAL, Preeti, G., P.O. Box 5142, Santa Clara, CA 95056,
US [IN, US];
LU, Dyung, Aina, M., 233 Coy Drive, San Jose, CA 95123,
US [US, US];
SWARNAKER, Anita, 8 Locksley Avenue, #5D, San
Francisco, CA 94122, US [CA, US];
JONES, Karen, Anne, 2 Castle Court, Saffron Walden,
Essex CB10 1BH, GB [GB, GB];
RING, Huijun, Z., 625 Orange Avenue, Los Altos, CA
94022, US [US, US]
PATENT ASSIGNEE(S): INCYTE GENOMICS, INC., 3160 Porter Drive, Palo Alto, CA
94304, US [US, US], for all designates States except
US;
SANJANWALA, Madhusudan, M., 210 Silvia Court, Los
Altos, CA 94024, US [US, US], for US only;
LU, Yan, 3885 Corrina Way, Palo Alto, CA 94303, US [CN,
US], for US only;
LEE, Ernestine, A., 624 Kains Street, Albany, CA 94706,
US [US, US], for US only;
HAHALIA, April, J., A., 2227 Calle de Primavera, Santa
Clara, CA 95054, US [US, US], for US only;
WARREN, Bridget, A., 10130 Parkwood Drive #2,
Cupertino, CA 95014, US [US, US], for US only;
BAUGHN, Mariah, R., 14244 Santiago Road, San Leandro,
CA 94577, US [US, US], for US only;
TANG, Tom, Y., 4230 Ranwick Court, San Jose, CA 95118,
US [US, US], for US only;
YUE, Henry, 826 Lois Avenue, Sunnyvale, CA 94087, US
[US, US], for US only;
YAO, Monique, G., 1189 Woodgate Drive, Carmel, IN
46033, US [US, US], for US only;
LEE, Sally, 825 East Evelyn, #425, Sunnyvale, CA 94086,
US [US, US], for US only;
THORNTON, Michael, 9 Medway Road, Woodside, CA 94062,
US [US, US], for US only;
WALIA, Narinder, K., 890 Davis Street #205, San
Leandro, CA 94577, US [US, US], for US only;
XU, Yuming, 1739 Walnut Drive, Mountain View, CA 94040,
US [US, US], for US only;
TRAN, Uyen, K., 2638 Mabury Square, San Jose, CA 95133,
US [US, US], for US only;
LAL, Preeti, G., P.O. Box 5142, Santa Clara, CA 95056,
US [IN, US], for US only;
LU, Dyung, Aina, M., 233 Coy Drive, San Jose, CA 95123,
US [US, US], for US only;
SWARNAKER, Anita, 8 Locksley Avenue, #5D, San
Francisco, CA 94122, US [CA, US], for US only;
JONES, Karen, Anne, 2 Castle Court, Saffron Walden,
Essex CB10 1BH, GB [GB, GB], for US only;
RING, Huijun, Z., 625 Orange Avenue, Los Altos, CA
94022, US [US, US], for US only
AGENT: HAMLET COX, Diana\$, Incyte Genomics, Inc., 3160 Porter
Drive, Palo Alto, CA 94304\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002064795	A2	20020822

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

RW (EAPO):

RW (EPO):

RW (OAPI):

APPLICATION INFO.:

PRIORITY INFO.:

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WO 2002-US3814 A 20020208

US 2001-60/268,113 20010209

US 2001-60/269,215 20010215

US 2001-60/272,271 20010227

US 2001-60/274,091 20010307

US 2001-60/274,423 20010309

US 2001-60/278,480 20010323

US 2001-60/278,479 20010323

ABEN The invention provides human enzymes (NZMS) and polynucleotides which identify and encode NZMS. The invention also provides **expression** vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant **expression** of NZMS.

ABFR L'invention porte: sur des enzymes humaines (NZMS) et sur les polynucleotides les identifiant et codant pour elles, sur des vecteurs d'**expression**, des cellules hotes, des anticorps, des agonistes, et des antagonistes, et sur des methodes de diagnostic, traitement et prevention de troubles lies a l'**expression** aberrante de NZMS.

L50 ANSWER 30 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002064025 PCTFULL ED 20020904 EW 200234
TITLE (ENGLISH): INHIBITION OF ATF2 ACTIVITY TO TREAT CANCER
TITLE (FRENCH): TRAITEMENT DU CANCER PAR INHIBITION DE L'ACTIVITE DE
L'ATF2
INVENTOR(S): ZE'EV, Ronai, 3 Copeland Drive, Suffern, NA 10901, US
[US, US]
PATENT ASSIGNEE(S): MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY,
One Gustave Levy Place, New York, NY 10029, US [US,
US], for all designates States except US;
ZE'EV, Ronai, 3 Copeland Drive, Suffern, NA 10901, US
[US, US], for US only
AGENT: FEHLNER, Paul, F.S, Darby & Darby P.C., 805 Third
Avenue, New York, NY 10022-7513\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002064025	A2	20020822

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

RW (EAPO):

RW (EPO):

RW (OAPI):

APPLICATION INFO.:

PRIORITY INFO.:

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

AM AZ BY KG KZ MD RU TJ TM

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WO 2002-US5215 A 20020214

US 2001-60/269,118 20010215

US 2001-60/269,257 20010216

ABEN The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit apoptosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.

ABFR L'invention porte: sur de nouvelles therapies du cancer et en particulier sur des therapies particulierement adaptees aux cellules tumorales resistant aux autres types de therapies telles que les rayons, la chimiotherapie, ou leur combinaison consistant a identifier et mettre en oeuvre des strategies inhibant l'apoptose des cellules; sur un fragment inhibiteur N-terminal d'ATF2 et specifiquement sur un fragment (dit peptide II) correspondant aux residus d'acide amine 50-100 de l'ATF2; et sur des procedes d'inhibition de la croissance des cellules tumorales a l'aide de tels peptides.

L50 ANSWER 31 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002050284 PCTFULL ED 20020709 EW 200226
TITLE (ENGLISH): OXIDOREDUCTASES
TITLE (FRENCH): OXYDOREDUCTASES
INVENTOR(S): TRIBOULEY, Catherine, M., 1121 Tennessee Street, #5, San Francisco, CA 94107, US [FR, US]; LEE, Ernestine, A., 624 Kains Street, Albany, CA 94706, US [US, US]; YAO, Monique, G., 1189 Woodgate Drive, Carmel, IN 46033, US [US, US]; ELLIOTT, Vicki, S., 3770 Polten Place Way, San Jose, CA 95121, US [US, US]; YUE, Henry, 826 Lois Avenue, Sunnyvale, CA 94087, US [US, US]
PATENT ASSIGNEE(S): INCYTE GENOMICS, INC., 3160 Porter Drive, Palo Alto, CA 94304, US [US, US], for all designates States except US; TRIBOULEY, Catherine, M., 1121 Tennessee Street, #5, San Francisco, CA 94107, US [FR, US], for US only; LEE, Ernestine, A., 624 Kains Street, Albany, CA 94706, US [US, US], for US only; YAO, Monique, G., 1189 Woodgate Drive, Carmel, IN 46033, US [US, US], for US only; ELLIOTT, Vicki, S., 3770 Polten Place Way, San Jose, CA 95121, US [US, US], for US only; YUE, Henry, 826 Lois Avenue, Sunnyvale, CA 94087, US [US, US], for US only
AGENT: HAMLET-COX, Diana\$, Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2002050284 A2 20020627
DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 APPLICATION INFO.: WO 2001-US49131 A 20011218
 PRIORITY INFO.: US 2000-60/257,802 20001221
 US 2001-60/262,901 20010118
 ABEN The invention provides human oxido-reductases (OXRD) and polynucleotides which identify and encode OXRD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of OXRD.
 ABFR L'invention concerne des oxydoreductases humaines (OXRD) et des polynucleotides qui identifient et codent pour OXRD ; des vecteurs d'expression, des cellules hotes, des anticorps, des agonistes et des antagonistes ; ainsi que des methodes permettant de diagnostiquer, de traiter ou de prevenir des affections associees a l'expression aberrante de OXRD.

L50 ANSWER 32 OF 79 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 2002036624 PCTFULL ED 20020523 EW 200219
 TITLE (ENGLISH): METHODS AND COMPOSITIONS RELATING TO FORTILIN, AN ANTI-APOPTOTIC MOLECULE, AND MODULATORS OF FORTILIN
 TITLE (FRENCH): PROCEDES ET COMPOSITIONS ASSOCIES A LA FORTILINE, UNE MOLECULE ANTI-APOPTOTIQUE, ET MODULATEURS DE FORTILINE
 INVENTOR(S): FUJISE, Kenichi, 7900 Cambridge 16-2C, Houston, TX 77054, US [US, US]; YEH, Edward, 4012 Villanova, Houston, TX 77005, US [US, US]
 PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, 201 West 7th Street, Austin, TX 78701, US [US, US], for all designates States except US; FUJISE, Kenichi, 7900 Cambridge 16-2C, Houston, TX 77054, US [US, US], for US only; YEH, Edward, 4012 Villanova, Houston, TX 77005, US [US, US], for US only
 AGENT: SHISHIMA, Gina, N.S., Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX 78701\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 2002036624	A2	20020510

 DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US42985 A 20011030
 PRIORITY INFO.: US 2000-60/244,416 20001030

 ABEN The polypeptide Fortilin (also known as Translationally Controlled Tumour Protein, TCTP) specifically interacts with p53, a tumor suppressor involved in the induction of apoptosis and the normal growth regulation of a cell. Fortilin also specifically binds MCL1 (Myeloid Cell Leukemia 1). Fortilin has the ability to prevent apoptosis, which may be unregulated in hyperproliferative cells. The present invention is directed at compositions and methods involving a Fortilin modulator, which can induce apoptosis, for the prevention, treatment, or diagnosis of hyperproliferative diseases and conditions, including cancer and

atherosclerosis. It is directed also at compositions and methods involving Fortilin, which can inhibit apoptosis, for the treatment of diseases and condition characterized by apoptosis, including certain vascular conditions.

ABFR Le polypeptide fortiline (egalement appele proteine tumorale de regulation de traduction, TCTP) interagit specifiquement avec p53, un suppresseur de tumeur intervenant dans l'induction de l'apoptose et la regulation de la croissance normale d'une cellule. La fortiline se lie aussi specifiquement a MCL1 (leucemie myeloide 1). La fortiline est capable de prevenir l'apoptose, qui peut etre dereglee dans des cellules hyperproliferatives. L'invention concerne des compositions et des procedes comprenant un modulateur de fortiline, capable d'induire l'apoptose, pour prevenir, traiter ou diagnostiquer des maladies ou des affections hyperproliferatives, y compris le cancer et l'atheroscleroze ; ainsi que des compositions et des procedes comprenant la fortiline, capable d'inhiber l'apoptose, pour traiter des maladies et affections caracterisees par l'apoptose, y compris certaines affections vasculaires.

L50 ANSWER 33 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002029032 PCTFULL ED 20020627 EW 200215
TITLE (ENGLISH): WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL
PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND
OPTIONALLY REPEATING
TITLE (FRENCH): MANIPULATION DE CELLULE ENTIERE PAR MUTAGENESE D'UNE
PARTIE SUBSTANTIELLE D'UN GENOME DE DEPART, PAR
COMBINAISON DE MUTATIONS ET EVENTUELLEMENT PAR
REPETITION
INVENTOR(S): SHORT, Jay, M., P.O. Box 7214, Rancho Santa Fe, CA
92067-7214, US [US, US];
FU, Pengcheng, 7588 Charmant Drive #1914, San Diego, CA
92122-5079, US [AU, US];
LATTERICH, Martin, 12539 Motellano Terrace, San Diego,
CA 92130, US [DE, US];
WEI, Jing, 10725 Wexford St. #6, San Diego, CA 92131,
US [CN, US];
LEVIN, Michael, 7565 Tupelo Cove, San Diego, CA 92126,
US [RU, US]
PATENT ASSIGNEE(S): DIVERSA CORPORATION, 4955 Directors Place, San Diego,
CA 92121, US [US, US], for all designates States except
US;
SHORT, Jay, M., P.O. Box 7214, Rancho Santa Fe, CA
92067-7214, US [US, US], for US only;
FU, Pengcheng, 7588 Charmant Drive #1914, San Diego, CA
92122-5079, US [AU, US], for US only;
LATTERICH, Martin, 12539 Motellano Terrace, San Diego,
CA 92130, US [DE, US], for US only;
WEI, Jing, 10725 Wexford St. #6, San Diego, CA 92131,
US [CN, US], for US only;
LEVIN, Michael, 7565 Tupelo Cove, San Diego, CA 92126,
US [RU, US], for US only
AGENT: EINHORN, Gregory, P.S, Fish & Richardson P.C., 4350 La
Jolla Village Drive, San Diego, CA 92122\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2002029032 A2 20020411
DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK

SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US31004 A 20011001
PRIORITY INFO.: US 2000-09/677,584 20000930
US 2001-60/279,702 20010328
US 2001-PCT/US01/19367 20010614

ABEN An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. In one embodiment, this invention provides a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. This invention also provides a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, this conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. This invention also provides a method of generating novel host organisms having **increased expression** of desirable traits, recombinant genes, and gene products. This invention provides novel methods for determining polypeptide profiles, and protein **expression** variations, which methods are applicable to all sample types disclosed herein. The present invention provides methods of simultaneously identifying and quantifying individual proteins in complex protein mixtures. Additionally this invention provides methods for cellular and metabolic engineering of new and modified phenotypes by using on-line or real-time metabolic flux analysis.

ABFR L'invention concerne des procedes de transformation cellulaire, d'evolution dirigee et de criblage utiles pour produire de nouveaux organismes transgeniques possedant des proprietes voulues. Dans une forme de realisation, l'invention concerne un procede de **production** d'organisme transgenique, tel qu'un microbe ou une plante, comportant une pluralite de caracteristiques activables de maniere differenciee. L'invention concerne aussi un procede de remaniement de genes et de voies geniques par l'introduction de sequences regulatrices, tels des promoteurs, qui peuvent etre activees chez un hote voulu et sont ainsi capables de conferer une capacite d'activation a une nouvelle voie genique apres introduction de celle-ci dans un hote voulu; par exemple, une nouvelle voie genique artificielle, produite sur la base de modeles de progeniteurs derives de microbes, qui peut etre activee dans une cellule vegetale. Cette invention concerne aussi un procede de **production** de nouveaux organismes hotes possedant une **expression** accrue de caracteristiques voulues, de

genes recombinés et de produits géniques; de nouveaux procédés servant à déterminer des profils de polypeptides et des variations d'**expression** de protéines, ces procédés pouvant être appliqués à tous les types d'échantillons décrits; des procédés permettant d'identifier et de quantifier simultanément des protéines individuelles dans des mélanges complexes de protéines. De plus, l'invention concerne des procédés de mise au point cellulaire et métabolique de nouveaux phénotypes modifiés utilisant une analyse de flux métabolique ; en ligne ; ou et en temps réel ;.

L50 ANSWER 34 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002026951 PCTFULL ED 20020701 EW 200214
TITLE (ENGLISH): OXIDOREDUCTASES
TITLE (FRENCH): OXYDOREDUCTASES
INVENTOR(S): BAUGHN, Mariah, R., 14244 Santiago Road, San Leandro, CA 94577, US [US, US];
YUE, Henry, 826 Lois Avenue, Sunnyvale, CA 94087, US [US, US];
TRIBOULEY, Catherine, M., 1121 Tennessee Street #5, San Francisco, CA 94107, US [FR, US];
LEE, Ernestine, A., 624 Kains Street, Albany, CA 94706, US [US, US];
HAFALIA, April, J., A., 2227 Calle de Primavera, Santa Clara, CA 95054, US [US, US];
SANJANWALA, Madhu, S., 210 Sylvia Court, Los Altos, CA 94024, US [US, US];
YAO, Monique, G., 111 Frederick Court, Mountain View, CA 94043, US [US, US];
DING, Li, 3353 Alma Street, #146, Palo Alto, CA 94306, US [CN, US];
ELLIOTT, Vicki, S., 3770 Polton Place, San Jose, CA 95121, US [US, US]
PATENT ASSIGNEE(S): INCYTE GENOMICS INC, 3160 Porter Drive, Palo Alto, CA 94304, US [US, US], for all designates States except US;
BAUGHN, Mariah, R., 14244 Santiago Road, San Leandro, CA 94577, US [US, US], for US only;
YUE, Henry, 826 Lois Avenue, Sunnyvale, CA 94087, US [US, US], for US only;
TRIBOULEY, Catherine, M., 1121 Tennessee Street #5, San Francisco, CA 94107, US [FR, US], for US only;
LEE, Ernestine, A., 624 Kains Street, Albany, CA 94706, US [US, US], for US only;
HAFALIA, April, J., A., 2227 Calle de Primavera, Santa Clara, CA 95054, US [US, US], for US only;
SANJANWALA, Madhu, S., 210 Sylvia Court, Los Altos, CA 94024, US [US, US], for US only;
YAO, Monique, G., 111 Frederick Court, Mountain View, CA 94043, US [US, US], for US only;
DING, Li, 3353 Alma Street, #146, Palo Alto, CA 94306, US [CN, US], for US only;
ELLIOTT, Vicki, S., 3770 Polton Place, San Jose, CA 95121, US [US, US], for US only
AGENT: HAMLET-COX, Diana\$, Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2002026951 A2 20020404
DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR

CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM
 AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR
 RW (ARIPO) : BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
 RW (EAPO) : WO 2001-US30656 A 20010928
 RW (EPO) : US 2000-60/237,101 20000929
 RW (OAPI) : US 2000-60/238,482 20001006
 APPLICATION INFO. : US 2000-60/244,024 20001027
 PRIORITY INFO. : US 2000-60/250,805 20001201

ABEN The invention provides human oxidoreductases (OXIRED) and polynucleotides which identify and encode OXIRED. The invention also provides **expression** vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant **expression** of OXIRED.
 ABFR La presente invention concerne des oxydoreductases (OXIRED) humaines et des polynucleotides qui identifient et codent OXIRED. Cette invention concerne aussi des vecteurs d'**expression**, des cellules hotes, des anticorps, des agonistes et des antagonistes. Cette invention concerne enfin des techniques de diagnostic, de traitement et de prevention de pathologies associees a une **expression** aberrante d'OXIRED.

L50 ANSWER 35 OF 79 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 2002014480 PCTFULL ED 20020711 EW 200208
 TITLE (ENGLISH): DECELLULARIZED TISSUE ENGINEERED CONSTRUCTS AND TISSUES
 TITLE (FRENCH): CONSTRUCTIONS DE TISSU DECELLULARISE ISSUES DE
 INVENTOR(S): L'INGENIERIE TISSULAIRE ET TISSUS AINSI PRODUITS
 MITCHELL, Shannon, 1717 Pergin Farm Road, Oakland, MD
 21550, US [US, US];
 KOH, Jennifer, 11 Laurelglen, Irvin, CA 92614, US [US, US];
 NIKLASON, Laura, E., 3301 Carriage Tr., Hillsborough, NC 27278, US [US, US];
 PRABHAKAR, Vikas, Durham, NC 27708, US [US, US]
 PATENT ASSIGNEE(S): DUKE UNIVERSITY, 230 North Building, Research Drive, Durham, NC 27708, US [US, US], for all designates States except US;
 MITCHELL, Shannon, 1717 Pergin Farm Road, Oakland, MD 21550, US [US, US], for US only;
 KOH, Jennifer, 11 Laurelglen, Irvin, CA 92614, US [US, US], for US only;
 NIKLASON, Laura, E., 3301 Carriage Tr., Hillsborough, NC 27278, US [US, US], for US only;
 PRABHAKAR, Vikas, Durham, NC 27708, US [US, US], for US only
 AGENT: GERBER, Monica\$, Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA 02109\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002014480	A2	20020221

DESIGNATED STATES
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL

TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US25628 A 20010816
PRIORITY INFO.: US 2000-60/225,698 20000816
US 2001-60/225,698 20010816

ABEN New methods for producing tissue engineered constructs and engineered native tissues are disclosed. The methods include producing a tissue engineered construct by growing cells *in vitro* on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for **production of** the construct, the developing construct may be subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. The methods also include producing an engineered native tissue by harvesting tissue from an animal or human, performing one or more tissue engineering steps on the tissue, and subjecting the tissue to decellularization. The decellularized, engineered native tissue may then be subjected to further tissue engineering steps.

ABFR L'invention concerne des nouvelles méthodes destinées à produire des constructions de tissu et des tissus endogènes à l'aide de techniques d'ingénierie tissulaire. Ces méthodes consistent à produire une construction de tissu par développement de cellules *in vitro* sur un substrat, puis par décellularisation de cette construction en vue d'obtenir une construction décellularisée constituée en grande partie de composants de matrice extracellulaire. Cette construction peut être utilisée immédiatement ou stockée en vue d'une utilisation ultérieure. La construction décellularisée peut être destinée au développement d'un tissu par ingénierie tissulaire, technique pouvant consister à ensemencer ladite construction avec des cellules provenant du receveur correspondant. Pendant n'importe laquelle des phases de développement requises pour la **production** de cette construction, la construction en développement peut être soumise à plusieurs opérations d'ingénierie tissulaire, et notamment à l'application de stimuli mécaniques tels que des forces pulsatiles. Ces méthodes consistent également à produire un tissu endogène par culture d'un tissu animal ou humain, à effectuer une ou plusieurs opérations d'ingénierie tissulaire sur ce tissu, puis à soumettre ledit tissu à une décellularisation. On peut ensuite soumettre le tissu endogène décellularisé résultant à des opérations supplémentaires d'ingénierie tissulaire.

L50 ANSWER 36 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2002011669 PCTFULL ED 20020711 EW 200207
TITLE (ENGLISH): COMPOSITIONS COMPRISING HEAT SHOCK PROTEINS OR

ALPHA(2)MACROGLOBULIN, ANTIGENIC MOLECULES AND
 SAPONINS, AND METHODS OF USE THEREOF
 COMPOSITIONS COMPRENANT DES PROTEINES DE CHOC THERMIQUE
 OU ALPHA(2)MACROGLOBULINES, DES MOLECULES ANTIGENIQUES
 ET DES SAPONINES, ET PROCEDES D'UTILISATION ASSOCIES
 INVENTOR(S): ARMEN, Garo, H., 66 Mayfair Lane, Manhasset, NY 11030,
 US
 PATENT ASSIGNEE(S): ANTIGENICS, LLC, Suite 2100, 630 Fifth Avenue, New
 York, NY 10011, US [US, US]
 AGENT: ANTLER, Adriane, M. \$, Pennie & Edmonds LLP, 1155
 Avenue of the Americas, New York, NY 10036\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002011669	A2	20020214

DESIGNATED STATES
 W: AU CA JP
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
 TR

APPLICATION INFO.: WO 2001-US23098 A 20010720
 PRIORITY INFO.: US 2000-60/223,133 20000807

ABEN The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (α 2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsps that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or α 2M, free in solution, and/or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or α 2M-antigenic molecule complex.

ABFR L'invention concerne des compositions pharmaceutiques ainsi que des procedes, destines a la prevention et au traitement de maladies auto-immunes, infectieuses ou neurodegeneratives, et de maladies neoplasiques primaires ou metastatiques. En pratique et selon l'invention, on emploie des compositions comprenant: (a) une proteine de choc thermique (hsp) ou une alpha-2-macroglobuline, (b) une saponine, et eventuellement (c) une molecule antigenique. Cette molecule antigenique possede l'antigenicite d'un antigene (a) d'une cellule provoquant une reponse auto-immune, (b) d'un agent d'une maladie infectieuse, (c) d'une cellule cancreuse ou (d) d'une cellule ou structure associee a une maladie neurodegenerative ou amyloide. Les proteines de choc thermique (hsp) que l'on peut utiliser dans la mise en oeuvre de l'invention comprennent, sans y etre limitees, les proteines hsp70, hsp90, gp96, calreticuline, hsp110, grp170, et PDI, seules ou combinees les unes avec les autres. La molecule antigenique peut etre liee de maniere covalente ou non a la proteine de choc thermique ou a l'alpha-2-macroglobuline, placee libre dans une solution, et/ou liee de maniere covalente a la saponine. Les compositions selon l'invention peut etre administrees seules ou combinees a l'administration de cellules presentant un antigene et sensibilisees a l'aide d'un complexe d'une proteine de choc thermique ou d'une alpha(2)macroglobuline, et d'une molecule antigenique.

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 574391 EUROPATFULL EW 200226 FS PS
 TITLE: ANTIBODIES AGAINST THE UROKINASE RECEPTOR AND THEIR USE.
 ANTIKOeRPER GEGEN DEN UROKINASEREZEPTOR UND IHRE
 VERWENDUNG.
 ANTICORPS CONTRE LE RECEPTEUR DE L'UROKINASE ET LEUR
 UTILISATION.

INVENTOR(S): DAN, Keld, L.E. Bruuns Vej 20, DK-2920 Charlottenlund,
 DK;
 RONNE, Ebbe, Kurlandsvej 18, 1.tv., DK-2300 Copenhagen
 S, DK;
 BEHRENDT, Niels, Langemosevej 17, DK-2880 Bagsvaerd, DK;
 ELLIS, Vincent, Nyhavn 18, DK-1051 Copenhagen K, DK;
 HOYER-HANSEN, Gunilla, Toftekaersvej 67, DK-2820
 Gentofte, DK;
 PYKE, Charles, Carl Mollers Alle 18, 1.th., DK-2860
 Soborg, DK;
 BRUENNER, Nils, Benvedvaenget 9, DK-2830 Virum, DK
 Cancerforskningfonden af 1989 (fonden til fremme af
 eksperimentel cancerforskning), c/o attorney Michael
 Rostock Vester Voldgade 90, DK-1552 Copenhagen V, DK

PATENT ASSIGNEE(S): 1295820

PATENT ASSIGNEE NO: 1295820

AGENT: Plougmann, Vingtoft & Partners A/S, Sankt Annae Plads
 11, P.O. Box 3007, 1021 Copenhagen K, DK

AGENT NUMBER: 101171

OTHER SOURCE: BEPB2002045 EP 0574391 B1 0103

SOURCE: Wila-EPS-2002-H26-T1

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FR; R GB; R GR; R
 IT; R LI; R LU; R NL; R SE

PATENT INFO. PUB. TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale
 Anmeldung)

PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 574391	B1	20020626
APPLICATION INFO.:	EP 1991-918632		19911018
PRIORITY APPLN. INFO.:	DK 1990-270		19901018
RELATED DOC. INFO.:	WO 91-DK319	911018	INTAKZ
	WO 9207083	920430	INTPNR
REFERENCE PAT. INFO.:	EP 278696 A	EP 381303 A	
	WO 90-12091 A		
REF. NON-PATENT-LIT.:	The Journal of Biological Chemistry, volume 265, no. 11, 15 April 1990 (Baltimore, US) N. Behrendt et al.: "The human receptor for urokinase plasminogen activator", pages 6543-6460, see the whole article FEBS Letters, volume 288, no. 1,2, August 1991, Elsevier Science Publishers B.V. (Amsterdam, NL) E. Ronne et al.: "Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor", pages 233-236, see the whole article Cell Differentiation and Development, volume 32, no. 3, 11 December 1990, Proceedings of the 13th Sigrid Juselius Symposium, Helsinki, 12-15 August 1990, F. Blasi et al.: "The urokinase receptor and regulation of cell surface plasminogen activation", pages 247-254, see the whole article, especially page 251 Cancer Research, volume 50, 1 May 1990 (Philadelphia, US) Wen-Chang Lin et al.: "Bacterial lacZ gene as a highly sensitive marker to		

detect micrometastasis formation during tumor progression", pages 2808-2817, see the whole article The Journal of Cell Biology, volume 107, no. 6, December 1988, The Rockefeller University Press (New York, US) L. Ossowski: "In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase", pages 2437-2445, see the whole article Proceedings of the National Academy of Sciences, volume 86, July 1989, Cell Biology (US) J.C. Kirchheimer et al.: "Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line", pages 5424-5428, see the whole article Biological Abstracts, volume 82, 1986, (Philadelphia, PA, US) G. Fibbi et al. "The 17500 molecular weight region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells", page AB-355, abstract nr. 12855, see the abstract Biological Abstracts, volume 85, 1988, (Philadelphia, PA, US) V.J. Hearing et al.: "Modulation of metastatic potential by cell surface urokinase of murine melanoma cells", page A-645, abstract no. 102514, see the abstract

L50 ANSWER 38 OF 79 USPATFULL
 ACCESSION NUMBER: 2001:194406 USPATFULL
 TITLE: Osteopontin-derived chemotactic and inhibitory agents and uses therefor
 INVENTOR(S): Ashkar, Samy, Boston, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001036921	A1	20011101
APPLICATION INFO.:	US 2000-729873	A1	20001205 (9)
PRIORITY INFORMATION:	WO 2000-US10344		20000417
	US 1999-129764P		19990415 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1763		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Novel osteopontin-derived chemotactic and inhibitory agents are described. Methods of using these agents are also described.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 39 OF 79 USPATFULL
 ACCESSION NUMBER: 2001:188410 USPATFULL
 TITLE: Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
 INVENTOR(S): Srivastava, Pramod K., Avon, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001034042	A1	20011025
APPLICATION INFO.:	US 2001-759010	A1	20010112 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-488393, filed on 20 Jan 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW		

YORK, NY, 100362711

NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions comprising peptide-binding fragments of heat shock proteins (HSPs) and noncovalent complexes of peptide-binding fragments of HSPs in noncovalent association with antigenic molecules. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for the treatment and prevention of infectious diseases and cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 40 OF 79 USPATFULL
ACCESSION NUMBER: 2001:235082 USPATFULL
TITLE: Genes encoding several poly (ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith
INVENTOR(S): Jacobson, Myron K., Lexington, KY, United States
Jacobson, Elaine L., Lexington, KY, United States
Ame, Jean-Christophe, Obernai, France
Lin, Winston, Lexington, KY, United States
PATENT ASSIGNEE(S): University of Kentucky Research, Lexington, KY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333148	B1	20011225
APPLICATION INFO.:	US 1999-302812		19990430 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83768P	19980501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Brusca, John S.	
ASSISTANT EXAMINER:	Lacourciere, Karen A	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski, LLP	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	2518	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The isolation and characterization of cDNAs encoding poly(ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in *E. coli* results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 41 OF 79 USPATFULL
ACCESSION NUMBER: 2001:197264 USPATFULL
TITLE: Maize aquaporins and uses thereof
INVENTOR(S): Jung, Rudolf, Des Moines, IA, United States
Chaumont, Francois, Louvain-la-Neuve, Belgium
Chrispeels, Maarten, La Jolla, CA, United States
PATENT ASSIGNEE(S): Pioneer Hi-Bred International, Inc., Des Moines, IA,
United States (U.S. corporation)
The Regents of the University of California, Oakland,
CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6313376	B1	20011106
APPLICATION INFO.:	US 1999-372448		19990811 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96627P	19980814 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fox, David T.	
ASSISTANT EXAMINER:	Ibrahim, Medina A.	
LEGAL REPRESENTATIVE:	Pioneer Hi-Bred International, Inc.	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1,4,5,8,13	
LINE COUNT:	3369	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated maize aquaporin nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering aquaporin concentration and/or composition of plants. The invention further provides recombinant **expression** cassettes, host cells, transgenic plants, and antibody compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 42 OF 79 USPATFULL
ACCESSION NUMBER: 2001:197263 USPATFULL
TITLE: Maize aquaporins and uses thereof
INVENTOR(S): Jung, Rudolf, Des Moines, IA, United States
Barrieu, Francois, Bordeaux, France
PATENT ASSIGNEE(S): Pioneer Hi-Bred International, Inc., Des Moines, IA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6313375	B1	20011106
APPLICATION INFO.:	US 1999-372422		19990811 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-98692P	19980813 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fox, David T.	
ASSISTANT EXAMINER:	Ibrahim, Medina A.	
LEGAL REPRESENTATIVE:	Pioneer Hi-Bred International, Inc.	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3234	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated maize aquaporin nucleic acids and their encoded proteins. The present invention provides methods and

compositions relating to altering aquaporin concentration and/or composition of plants. The invention further provides recombinant **expression** cassettes, host cells, transgenic plants, and antibody compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 43 OF 79 USPATFULL
ACCESSION NUMBER: 2001:97669 USPATFULL
TITLE: Method for inactivating non-enveloped viral
contaminants with a photosensitizer by increasing viral
permeability to the photosensitizer
INVENTOR(S): Sowemimo-Coker, Samuel O., Arcadia, CA, United States
Goodrich, Jr., Raymond P., Pasadena, CA, United States
PATENT ASSIGNEE(S): Baxter International, Inc., Round Lake, IL, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251644	B1	20010626
APPLICATION INFO.:	US 1994-343680		19941122 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-311125, filed on 22 Sep 1994, now patented, Pat. No. US 5516629 Continuation-in-part of Ser. No. US 1993-165305, filed on 10 Dec 1993, now patented, Pat. No. US 5587490 Continuation-in-part of Ser. No. US 1993-91674, filed on 13 Jul 1993, now patented, Pat. No. US 5418130 Continuation-in-part of Ser. No. US 1993-47749, filed on 14 Apr 1993 Continuation-in-part of Ser. No. US 1991-685931, filed on 16 Apr 1991, now abandoned Continuation-in-part of Ser. No. US 1991-656254, filed on 15 Feb 1991, now abandoned Continuation-in-part of Ser. No. US 1990-632277, filed on 20 Dec 1990, now abandoned Continuation-in-part of Ser. No. US 1990-510234, filed on 16 Apr 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weber, Jon P.		
LEGAL REPRESENTATIVE:	Swanson & Bratschun, L.L.C.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	2198		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	A method is presented for inactivating non-enveloped viruses that may be contaminating a biological solution or suspension by mixing the solution or suspension with a photosensitizer to form a mixture, adjusting the operating conditions of the mixture so as to increase the permeability of the viruses to the photosensitizer, and then irradiating the adjusted mixture.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 44 OF 79 USPATFULL
ACCESSION NUMBER: 2001:29344 USPATFULL
TITLE: Method for the **production** and purification of
adenoviral vectors
INVENTOR(S): Zhang, Shuyuan, Sugar Land, TX, United States
Thwin, Capucine, Spring, TX, United States
Wu, Zheng, Sugar Land, TX, United States
Cho, Toohyon, Houston, TX, United States (4)
PATENT ASSIGNEE(S): Introgen Therapeutics, Inc., Austin, TX, United States
(U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6194191 B1 20010227
APPLICATION INFO.: US 1997-975519 19971120 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31329P	19961120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Mosher, Mary E.	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski	
NUMBER OF CLAIMS:	89	
EXEMPLARY CLAIM:	1,61,71,78,86	
NUMBER OF DRAWINGS:	44 Drawing Figure(s); 44 Drawing Page(s)	
LINE COUNT:	3867	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention addresses the need to improve the yields of viral vectors when grown in **cell culture** systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached **cell culture** system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 **production** with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the **increase** of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 45 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001096551 PCTFULL ED 20020826
TITLE (ENGLISH): WHOLE CELL ENGINEERING BY MUTAGENIZING A SUBSTANTIAL PORTION OF A STARTING GENOME, COMBINING MUTATIONS, AND OPTIONALLY REPEATING
TITLE (FRENCH): INGENIERIE CELLULAIRE COMPLETE PAR MUTAGENESE D'UNE PARTIE SUBSTANCIELLE D'UN GENOME DE DEPART, PAR COMBINAISON DE MUTATIONS ET EVENTUELLEMENT REPETITION
INVENTOR(S): SHORT, Jay, M.
PATENT ASSIGNEE(S): DIVERSA CORPORATION;
SHORT, Jay, M.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001096551	A2	20011220

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US19367 A 20010614
PRIORITY INFO.: US 2000-09/594,459 20000614
US 2000-09/677,584 20000930

ABEN An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction

of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having **increased expression** of desirable traits, recombinant genes, and gene products.

ABFR L'invention porte sur des procedes de transformation cellulaire, d'evolution dirigee et de criblage en vue de creer de nouveaux organismes transgeniques aux proprietes souhaitées. En variante, cette invention porte sur un procede de generation d'un organisme transgenique tel qu'un microbe ou une plante presentant une pluralite de caracteristiques pouvant etre activees de maniere differentielle. L'invention porte aussi sur un procede permettant de restructurer des genes et des mecanismes d'action genetiques par l'introduction de sequences regulatrices telles que des promoteurs pouvant agir dans un hote determine, ce qui confere une operabilite a un nouveau mecanisme d'action genetique lorsqu'il est introduit dans un hote determine. Par exemple, un nouveau mecanisme d'action genetique artificiel, genere a partir de gabarits de progeniteurs derives de microbes, peut etre utilise dans une cellule vegetale. L'invention porte en poutre sur de nouveaux organismes hotes dont les caracteristiques souhaitées, les genes de recombinaison et les produits geniques ont une **expression accrue**.

L50 ANSWER 46 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001068836 PCTFULL ED 20020822
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR RNA INTERFERENCE
TITLE (FRENCH): PROCEDES ET COMPOSITIONS D'INTERFERENCE D'ARN
INVENTOR(S): BEACH, David;
BERNSTEIN, Emily;
CAUDY, Amy;
HAMMOND, Scott;
HANNON, Gregory
PATENT ASSIGNEE(S): GENETICA, INC.;
COLD SPRING HARBOR LABORATORY;
BEACH, David;
BERNSTEIN, Emily;
CAUDY, Amy;
HAMMOND, Scott;
HANNON, Gregory
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2001068836 A2 20010920
DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US8435 A 20010316
PRIORITY INFO.: US 2000-60/189,739 20000316
US 2000-60/243,097 20001024

ABEN The present invention provides methods for attenuating gene **expression** in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the "target" gene).
ABFR L'invention concerne des procedes servant a attenuer l'

expression d'un gene dans une cellule au moyen d'un ARN bicaudaire (ARNds) dirige vers un gene cible. Cet ARNdn contient une sequence de nucleotides s'hybridant dans des conditions physiologiques de la cellule, a la sequence de nucleotides d'au moins une partie du gene a inhiber (le gene "cible").

L50 ANSWER 47 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001052890 PCTFULL ED 20020827
TITLE (ENGLISH): HEAT SHOCK/**STRESS** PROTEIN COMPLEXES AS
VACCINES AGAINST NEURODEGENERATIVE DISORDERS
TITLE (FRENCH): COMPLEXES DE PROTEINES DE CHOC THERMIQUE/**STRESS**
UTILISES EN TANT QUE VACCINS CONTRE LES TROUBLES
NEURODEGENERATIFS
INVENTOR(S): SRIVASTAVA, Pramod, K.
PATENT ASSIGNEE(S): UNIVERSITY OF CONNECTICUT HEALTH CENTER
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2001052890 A1 20010726

DESIGNATED STATES
W: AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR

APPLICATION INFO.: WO 2001-US1825 A 20010118
PRIORITY INFO.: US 2000-09/489,216 20000121

ABEN The present invention relates to pharmaceutical compositions comprising complexes of heat shock proteins (hsps) in association with antigenic molecules for use in treatment and prevention of neurodegenerative disorders and disease. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for the treatment and prevention of neurodegenerative disorders and disease.
ABFR L'invention concerne des preparations pharmaceutiques comprenant des complexes de protéines de choc thermique (hsp) associés à des molécules antigéniques, à utiliser dans le traitement et la prévention de troubles et de maladies neurodégénératives. L'invention porte également sur des procédés d'utilisation desdites préparations pharmaceutiques en tant qu'agents immunotherapeutiques pour le traitement et la prévention de troubles et de maladies neurodégénératifs.

L50 ANSWER 48 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001052791 PCTFULL ED 20020827
TITLE (ENGLISH): COMPLEXES OF PEPTIDE-BINDING FRAGMENTS OF HEAT SHOCK PROTEINS AND THEIR USE AS IMMUNOTHERAPEUTIC AGENTS
TITLE (FRENCH): COMPLEXES DE FRAGMENTS DE LIAISON PEPTIDIQUE DE PROTEINES DE CHOC THERMIQUE ET LEUR UTILISATION COMME AGENTS IMMUNOTHERAPEUTIQUES
INVENTOR(S): SRIVASTAVA, Pramod, K.
PATENT ASSIGNEE(S): UNIVERSITY OF CONNECTICUT HEALTH CENTER
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2001052791 A2 20010726

DESIGNATED STATES
W: AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE TR

APPLICATION INFO.: WO 2001-US1781 A 20010118
PRIORITY INFO.: US 2000-09/488,393 20000120

ABEN The present invention relates to pharmaceutical compositions comprising peptide-binding fragments of heat shock proteins (HSPs) and noncovalent complexes of peptide-binding fragments of HSPs in noncovalent association with antigenic molecules. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for the treatment and prevention of infectious diseases and cancer.

ABFR La presente invention concerne des compositions pharmaceutiques comprenant des fragments de liaison peptidique de proteines de choc thermique (HSPs) et des complexes non covalents de fragments de liaison peptidique de HSPs en association non covalente avec des molecules antigeniques. L'invention concerne egalement des methodes d'utilisation de ces compositions pharmaceutiques comme agents immunotherapeutiques dans le traitement et la prevention des maladies infectieuses et du cancer.

L50 ANSWER 49 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001042451 PCTFULL ED 20020827
TITLE (ENGLISH): FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
TITLE (FRENCH): ADNC HUMAINS PLEINE LONGUEUR CODANT POUR DES PROTEINES POTENTIELLEMENT SECRETEES
INVENTOR(S): DUMAS MILNE EDWARDS, Jean-Baptiste;
BOUGUELERET, Lydie;
JOBERT, Severin
PATENT ASSIGNEE(S): GENSET;
DUMAS MILNE EDWARDS, Jean-Baptiste;
BOUGUELERET, Lydie;
JOBERT, Severin
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 2001042451 A2 20010614
DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2000-IB1938 A 20001207
PRIORITY INFO.: US 1999-60/169,629 19991208
US 2000-60/187,470 20000306

ABEN The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the **production of expression** vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET **expression** and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.
ABFR L'invention concerne des polynucleotides et des polypeptides GENSET. Ces produits GENSET peuvent s'utiliser comme reactifs dans des analyses judiciaires, en tant que marqueurs chromosomiques, comme marqueurs specifiques a un tissu/cellule/organite, dans la **production** de vecteurs d'**expression**. En outre, ils peuvent s'utiliser dans des dosages de criblage et diagnostiques d'une **expression** GENSET et/ou une activite biologique anormales ainsi que pour le criblage de composes pouvant etre utilises dans le traitement de troubles lies a GENSET.

L50 ANSWER 50 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001040292 PCTFULL ED 20020827
TITLE (ENGLISH): ANTIGEN-BINDING FRAGMENTS SPECIFIC FOR TUMOR ASSOCIATED ANTIGENS
TITLE (FRENCH): FRAGMENTS DE LIAISON A L'ANTIGENE SPECIFIQUES AUX ANTIGENES ASSOCIES AUX TUMEURS
INVENTOR(S): DAN, Michael;
ENTWISTLE, Joycelyn;
FAST, Darren;

KAPLAN, Howard;
LEWIS, Keith;
MACDONALD, Glen;
MAITI, Pradip
PATENT ASSIGNEE(S) : NOVOPHARM BIOTECH INC.;
DAN, Michael;
ENTWISTLE, Joycelyn;
FAST, Darren;
KAPLAN, Howard;
LEWIS, Keith;
MACDONALD, Glen;
MAITI, Pradip

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001040292	A1	20010607

DESIGNATED STATES

W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
ML MR NE SN TD TG

APPLICATION INFO.: WO 2099-CA1141 A 19991129

ABEN The present invention relates to antigen-binding fragments that are specific for stressprotein-peptide complexes specifically associated with tumors, particularly human tumors, and compositions thereof. The compositions are suitable for diagnostic and pharmaceutical use. The invention further provides methods of making and screening for the antigen-binding fragments. The invention further encompasses compositions containing cancer-associated **stress** protein-peptide complexes (including derivatives thereof) and methods of use thereof. The cancer-specific **stress** protein-peptide complexes ("SPPC"s) are particularly useful in eliciting cancer-specific immunogenic responses against a plurality of cancers. The invention also provides novel phage display libraries for use in producing further SPPCs and anti-SPPCs of the invention.

ABFR L'invention concerne des fragments de liaison a l'antigene qui sont specifiques aux complexes proteino-peptidiques sous tension plus particulierement associes aux tumeurs, aux tumeurs chez l'Homme en particulier, ainsi que les compositions de ces fragments. Les compositions sont adaptees a une utilisation pharmaceutique ou au diagnostic. L'invention concerne egalement les procedes de fabrication et de depistage des fragments de liaison a l'antigene. L'invention comprend aussi les compositions contenant des complexes proteino-peptidiques sous tension associes au cancer (y compris les derives de ces complexes) ainsi que leurs procedes d'utilisation. Les complexes proteino-peptidiques sous tension associes au cancer sont particulierement utiles au declenchement de reponses immunogenes specifiques au cancer pour lutter contre de nombreux cancers. L'invention concerne egalement des banques d'affichage des nouveaux phages qui sont utilisees pour la **production** de nouveaux complexes proteino-peptidiques sous tension et de nouveaux anti complexes proteino-peptidiques sous tension decrits dans l'invention.

L50 ANSWER 51 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001037857 PCTFULL ED 20020820
TITLE (ENGLISH): MAJOR INTRINSIC PROTEIN (MIP)-LIKE POLYNUCLEOTIDES,
POLYPEPTIDES, AND ANTIBODIES
TITLE (FRENCH): ANTICORPS, POLYPEPTIDES ET POLYNUCLEOTIDES DE TYPE MIP
(PROTEINE INTRINSEQUE MAJEURE)
INVENTOR(S): RUBEN, Steven, A.;

PATENT ASSIGNEE(S): NI, Jian
 HUMAN GENOME SCIENCES, INC.;
 RUBEN, Steven, A.;
 NI, Jian
 Patent

DOCUMENT TYPE: PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001037857	A1	20010531

DESIGNATED STATES
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US31919 A 20001121
 PRIORITY INFO.: US 1999-60/167,247 19991124

ABEN The present invention relates to novel human MIP-like polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human MIP-like polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human MIP-like polypeptides.

ABFR

L50 ANSWER 52 OF 79 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 2001032129 PCTFULL ED 20020820
 TITLE (ENGLISH): AUGMENTATION AND REPAIR OF AGE-RELATED SOFT TISSUE DEFECTS
 TITLE (FRENCH): AUGMENTATION ET REPARATION DES IMPERFECTIONS DES TISSUS MOUS LIES A L'AGE
 INVENTOR(S): KLEINSEK, Don, A.;
 SOTO, Adriana
 PATENT ASSIGNEE(S): GERIGENE MEDICAL CORPORATION;
 KLEINSEK, Don, A.;
 SOTO, Adriana

DOCUMENT TYPE: PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001032129	A2	20010510

DESIGNATED STATES
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
 CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
 JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
 MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
 TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ
 TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
 ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI
 CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US30623 A 20001106
 PRIORITY INFO.: US 1999-60/163,734 19991105

ABEN The present invention discloses methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair

follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect.

ABFR

L50 ANSWER 53 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2001000806 PCTFULL ED 20020828
TITLE (ENGLISH): COMPLEMENTARY DNA'S ENCODING PROTEINS WITH SIGNAL
PEPTIDES
TITLE (FRENCH): PROTEINES CODANT DES ADN COMPLEMENTAIRES AVEC DES
PEPTIDES-SIGNAL
INVENTOR(S): DUMAS MILNE EDWARDS, Jean-Baptiste;
BOUGUELERET, Lydie;
JOBERT, Severin
PATENT ASSIGNEE(S): GENSET;
DUMAS MILNE EDWARDS, Jean-Baptiste;
BOUGUELERET, Lydie;
JOBERT, Severin
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001000806	A2	20010104

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ
TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-IB951 A 20000621
PRIORITY INFO.: US 1999-60/141,032 19990625
US 1999-09/469,099 19991221

ABEN The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design **expression** vectors and secretion vectors.

ABFR

L50 ANSWER 54 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2000063247 PCTFULL ED 20020515
TITLE (ENGLISH): OSTEOPOONTIN-DERIVED CHEMOTACTIC AND INHIBITORY AGENTS
AND USES THEREFOR
TITLE (FRENCH): AGENTS CHIMIOTACTIQUES ET INHIBANTS TIRES DE
L'OSTEOPOONTINE ET LEURS UTILISATIONS
INVENTOR(S): ASHKAR, Samy
PATENT ASSIGNEE(S): CHILDREN'S MEDICAL CENTER CORPORATION;
ASHKAR, Samy
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2000063247	A2	20010126

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
 DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
 JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
 MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
 TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ
 UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES
 FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
 GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US10344 A 20000417

PRIORITY INFO.: US 1999-60/129,764 19990415

ABEN Novel osteopontin-derived chemotactic and inhibitory agents are described. Methods of using these agents are also described.

ABFR Cette invention concerne de nouveaux agents chimiotactiques et inhibants tires de l'osteopontine ainsi que des methodes relatives a leur utilisation.

L50 ANSWER 55 OF 79 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 2000044398 PCTFULL ED 20020515

TITLE (ENGLISH): METHODS FOR INCREASING CIRCULATING PLATELETS FOR COLLECTION AND CRYOPRESERVATION USING THROMBOPOIETIN COMPOSITIONS

TITLE (FRENCH): PROCEDES D'AUGMENTATION DE PLAQUETTES CIRCULANTES POUR PRELEVEMENT ET CRYOCONSERVATION AVEC DES COMPOSITIONS DE THROMBOPOIETINE

INVENTOR(S): VADHAN-RAJ, Saroj

PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000044398	A2	20000803

DESIGNATED STATES

W:

CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL
 PT SE

APPLICATION INFO.: WO 2000-US2173 A 20000128

PRIORITY INFO.: US 1999-09/239,442 19990128

US 1999-09/244,370 19990204

ABEN The present invention relates generally to the fields of platelet **production** in a patient and cryopreservation of platelets isolated from a patient. More particularly, it concerns transfusion of autologous or allogeneic cryopreserved platelets into a patient to prevent or manage thrombocytopenia.

ABFR La presente invention concerne de facon generale la **production** de plaquettes chez un patient, lesquelles sont ensuite isolees et conservees a tres basse temperature. Plus particulierement, cette invention concerne l'autotransfusion d'un patient avec des plaquettes allogeniques conservees a tres basses temperatures pour prevenir ou traiter la thrombocytopenie.

L50 ANSWER 56 OF 79 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 2000032754 PCTFULL ED 20020515

TITLE (ENGLISH): AN IMPROVED METHOD FOR THE **PRODUCTION** AND PURIFICATION OF ADENOVIRAL VECTORS

TITLE (FRENCH): PROCEDE AMELIORE DE **PRODUCTION** ET DE PURIFICATION DE VECTEURS ADENOVIRaux

INVENTOR(S): ZHANG, Shuyuan;
 THWIN, Capucine;
 WU, Zheng;
 CHO, Toohyon;

PATENT ASSIGNEE(S): GALLAGHER, Shawn
 INTROGEN THERAPEUTICS, INC.;
 ZHANG, Shuyuan;
 THWIN, Capucine;
 WU, Zheng;
 CHO, Toohyon;
 GALLAGHER, Shawn

LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000032754	A1	20000608

DESIGNATED STATES
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
 DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
 KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
 NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
 UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW
 AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
 ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US26966 A 19991116
 PRIORITY INFO.: US 1998-09/203,078 19981201

ABEN The present invention addresses the need to improve the yields of viral vectors when grown in **cell culture** systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached **cell culture** system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 **production** with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the **increase** of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

ABFR La presente invention se rapporte a la necessite d'ameliorer des rendements en vecteurs viraux obtenus par des procedes de culture cellulaires. Il a ete demonstre, en particulier, que pour les adenovirus, l'utilisation de vitesses de perfusion faibles a moyennes dans un systeme de culture cellulaire fixe permettait d'assurer un meilleur rendement. Dans d'autres modes de realisation, les inventeurs ont demonstre une **production** amelioree d'Ad-p53 avec des cellules cultivees dans un milieu sans serum, et en particulier dans une culture en suspension sans serum. L'utilisation d'une lyse a l'aide de detergents constitue egalement un facteur important dans l'accroissement des rendements. Lorsque les aspects de l'invention sont combines, les virus peuvent etre purifies en une seule etape chromatographique, ce qui permet d'obtenir des virus purifies ayant la meme qualite que des preparation effectuees a partir de double bandes de CsCl au moyen d'une ultracentrifugeuse.

L50 ANSWER 57 OF 79 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 2000012711 PCTFULL ED 20020515

TITLE (ENGLISH): HUMAN MEMBRANE CHANNEL PROTEINS

TITLE (FRENCH): PROTEINES MEMBRANAIRES DE CANAL HUMAINES

INVENTOR(S) : AU-YOUNG, Janice;
 BANDMAN, Olga;
 TANG, Y., Tom;
 REDDY, Roopa;
 HILLMAN, Jennifer, L.;
 YUE, Henry;
 LAL, Preeti;
 CORLEY, Neil, C.;
 GUEGLER, Karl, J.;
 GORGONE, Gina;
 BAUGHN, Mariah, R.;
 AZIMZAI, Yalda

PATENT ASSIGNEE(S) : INCYTE PHARMACEUTICALS, INC.;
 AU-YOUNG, Janice;
 BANDMAN, Olga;
 TANG, Y., Tom;
 REDDY, Roopa;
 HILLMAN, Jennifer, L.;
 YUE, Henry;
 LAL, Preeti;
 CORLEY, Neil, C.;
 GUEGLER, Karl, J.;
 GORGONE, Gina;
 BAUGHN, Mariah, R.;
 AZIMZAI, Yalda

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000012711	A2	20000309

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
 RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US
 US US US US US UZ VN YU ZW GH GM KE LS MW SD SL SZ
 UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES
 FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
 GN GW ML MR NE SN TD TG

APPLICATION INFO.:

	NUMBER	KIND	DATE
WO 1999-US20468	A	19990902	
US 1998-09/145,815		19980902	
US 1998-09/145,815		19980902	
US 1998-09/191,283		19981112	
US 1998-09/191,283		19981112	
US 1998-09/208,821		19981209	
US 1998-09/208,821		19981209	
US 1999-09/237,506		19990126	
US 1999-09/237,506		19990126	
US 1999-09/247,891		19990210	
US 1999-09/247,891		19990210	

PRIORITY INFO.:

ABEN The invention provides new human membrane channel proteins (MECHP) and polynucleotides which identify and encode MECHP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of MECHP.

ABFR L'invention concerne de nouvelles protéines membranaires de canal humaines (MECHP) et les polynucléotides qui identifient et codent pour MECHP. L'invention concerne également des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. L'invention concerne, en outre, des techniques de diagnostic, de traitement et de

prevention des troubles
associes a l'expression de MECHP.

L50 ANSWER 58 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 2000000225 PCTFULL ED 20020515
TITLE (ENGLISH): METHODS FOR REDUCING ADVENTITIOUS AGENTS AND TOXINS AND
CELL CULTURE REAGENTS PRODUCED
THEREBY
TITLE (FRENCH): PROCEDES SERVANT A REDUIRE DES AGENTS ET DES TOXINES
ADVENTICES ET REACTIFS DE CULTURES CELLULAIRES OBTENUS
AU MOYEN DE CES AGENTS ET DE CES TOXINES
INVENTOR(S): BIDDLE, William, C.;
FIKE, Richard, M.;
DADEY, Barbara, M.;
BULERA, Thomas, E.
PATENT ASSIGNEE(S): LIFE TECHNOLOGIES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000000225	A1	20000106

DESIGNATED STATES
W: JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
SE
APPLICATION INFO.: WO 1999-US14788 A 19990630
PRIORITY INFO.: US 1998-60/091,275 19980630
ABEN The invention relates to treating samples to reduce, substantially
reduce, inactivate, or
eliminate adventitious agents or toxins present in the sample of
interest. These ends are
accomplished by drying or substantially drying the sample.
ABFR L'invention concerne le traitement de specimens afin de reduire, reduire
sensiblement,
inactiver ou eliminer des agents ou des toxines adventices presents dans
ces specimens. Ce
traitement consiste a deshydrater le specimen, en totalite ou en partie.

L50 ANSWER 59 OF 79 USPATFULL
ACCESSION NUMBER: 1999:170440 USPATFULL
TITLE: Cell culturing method and medium
INVENTOR(S): Curcio, Francesco, Pagnacco, Italy
Coon, Hayden G., East Sebago, ME, United States
Ambesi-Impiombaro, F. Saverio, Udine, Italy
PATENT ASSIGNEE(S): Livercell L.L.C., East Sebago, ME, United States (U.S.
corporation)

NUMBER	KIND	DATE
US 6008047		19991228
US 1998-66897		19980428 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-480022, filed on 7 Jun 1993, now patented, Pat. No. US 5888816 which is a continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Tate, Christopher R.
LEGAL REPRESENTATIVE: Bancock Jr., John P.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 2290

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed **cell culture** of human liver cells comprising the steps of: (1) preparing partially purified, minced human liver tissue, (2) concentrating the resulting cells and tissue pieces, (3) resuspending the concentrated tissue cells and pieces in a growth medium, (4) culturing the resuspended cells in the growth medium for a time and under conditions to effect sustained cell division, and (5) passaging the cultured human liver cells periodically to expand the culture. The growth medium comprises a combination of a basal medium and ingredients to provide a medium in which the cultured human liver cells are selectively proliferated without being transformed, providing an expanded culture of proliferated, functionally differentiated human liver cells that is substantially free of fibroblast, macrophage and capillary endothelial cells. Also provided is the improvement of harvesting cells of the expanded culture at a selected PDL preferably >5, providing a high density cell suspension of such proliferated human liver cells, and incubating such high density cell suspension in a calm-down medium to induce a mitotically quiescent state and, using a culture procedure which encourages aggregation, making the cells adhere tightly to form a three-dimensional cell organization typical of the organ of origin, thereby forming organoids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 60 OF 79 USPATFULL

ACCESSION NUMBER: 1999:40236 USPATFULL

TITLE: **Cell cultures** of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells

INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy

PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5888816 19990330

APPLICATION INFO.: US 1995-480022 19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Lankford, Jr., Leon B.

ASSISTANT EXAMINER: Tate, Christopher R.

LEGAL REPRESENTATIVE: Bancock, John P.

NUMBER OF CLAIMS: 34

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)

LINE COUNT: 1992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded, enriched, non-transformed human **cell culture** of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells; (2) concentrating the desired cells; (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging; (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5)

passaging the cultured cells periodically to expand the culture. The present invention further provides clonal strains of cells derived from the above-mentioned **cell culture** and procedures to form matrix-embedded aggregated and non-aggregated cells for providing pseudotissues and products such as matrix-embedded pancreatic islets (pseudoislets). Growth medium and conditioned medium is provided for the culturing of the cells and clonal strains, the growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, serum and other ingredients, which growth medium selects in favor of desired human cells and against passenger cells including fibroblast, macrophage, and capillary endothelial cells such that the desired cells are selectively proliferated without being transformed and an expanded **cell culture** is provided of functionally differentiated, expanded, non-transformed human cells that is substantially free of such passenger cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 61 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1999054439 PCTFULL ED 20020515
TITLE (ENGLISH): ISOLATION AND PURGING OF CELLS BY MEANS OF OSMOTIC
PRESSURE
TITLE (FRENCH): ISOLATION ET PURGE CELLULAIRE PAR PRESSION OSMOTIQUE
INVENTOR(S): EPPICH, Henry, M.;
REILLY, Dennis, A.
PATENT ASSIGNEE(S): SCIENCE RESEARCH LABORATORY, INC.;
EPPICH, Henry, M.;
REILLY, Dennis, A.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:
NUMBER KIND DATE

WO 9954439 A1 19991028
DESIGNATED STATES
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG
APPLICATION INFO.: WO 1999-US8512 A 19990416
PRIORITY INFO.: US 1998-60/082,195 19980417
US 1998-60/103,944 19981013
ABEN The present invention involves methods and apparatuses which enable a selected population of biological cells to be isolated or purged from a cell mixture on the basis of a ratio of nuclear volume to total cell volume. According to the invention, osmotic pressure can be utilized to selectively lyse and/or render non-viable selected undesired subpopulations of cells in a suspension, while not adversely affecting other desired subpopulations. In some embodiments of the invention, cells can be selectively lysed or rendered non-viable on the basis of a ratio of nuclear volume to total cell volume by exposing the cells to a solution having a predetermined osmolarity selected to inactivate a substantial fraction of cells having a ratio of nuclear volume to total cell volume below a threshold value. The invention enables effective cell separation utilizing a

relatively rapid and easy to perform method involving changes in the osmolarity of cell suspensions.
The inventive method has a variety of potential applications in clinical medicine, research, etc., with two of the more important foreseeable applications being stem cell enrichment/isolation, and cancer cell purging.

ABFR La presente invention concerne des methodes et des appareils permettant d'isoler ou de purger une population choisie de cellules biologiques d'un melange cellulaire sur la base d'un rapport volume nucleaire/volume cellulaire total. Selon l'invention, on peut utiliser la pression osmotique pour lyser selectivement et/ou rendre non viables des sous-populations indesirables ciblees de cellules en suspension, sans porter prejudice a d'autres sous-populations desirees. Selon certains modes de realisation de l'invention, il est possible de selectivement lyser ou rendre non viables les cellules sur la base d'un rapport volume nucleaire/volume cellulaire total par exposition des cellules a une solution presentant une osmolarite predefinie choisie de maniere a inactiver une grande partie des cellules dont le rapport volume nucleaire/volume cellulaire total est inferieur a une valeur seuil. L'invention permet de separer efficacement les cellules grace a une methode relativement simple et rapide impliquant des changements d'osmolarite des suspensions cellulaires.
La methode de l'invention offre un large eventail d'applications eventuelles en medecine clinique, recherche, etc., les deux applications previsibles les plus importantes etant l'enrichissement/isolation de cellules souches, et la purge de cellules cancereuses.

L50 ANSWER 62 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1999029834 PCTFULL ED 20020515
TITLE (ENGLISH): METHODS FOR PREPARATION OF VACCINES AGAINST CANCER
TITLE (FRENCH): PROCEDES DE PREPARATION DE VACCINS CONTRE LE CANCER
INVENTOR(S): SRIVASTAVA, Pramod, K.
PATENT ASSIGNEE(S): FORDHAM UNIVERSITY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9929834	A1	19990617

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US26401 A 19981211
PRIORITY INFO.: US 1997-08/988,878 19971211

ABEN The present invention relates to methods for preparing immunogenic, prophylactically and therapeutically effective complexes of heat shock proteins noncovalently associated with antigenic peptides of cancer cells. The claimed methods comprise the constructing of a cDNA library from cancer or preneoplastic cell RNA, expressing the cDNA library in an

appropriate host cell, and recovering the immunogenic complexes from the cells. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the cDNA library. The complexes can be used as a vaccine to elicit specific immune responses against cancer or preneoplastic cells, and to treat or prevent cancer.

ABFR L'invention concerne des procedes servant a preparer des complexes immunogenes de proteines du **stress** prophylactiquement et therapeutiquement efficaces, associes de maniere non covalente a des peptides antigeniques de cellules cancereuses. Les procedes de l'invention consistent a construire une bibliotheque d'ADNC a partir de l'ARN d'une cellule cancereuse ou preneoplasique, a exprimer cette bibliotheque d'ADNC dans une cellule hote appropriee, et a recuperer les complexes immunogenes desdites cellules. On peut obtenir de grandes quantites de ces complexes immunogenes par culture a grande echelle de cellules hotes contenant la bibliotheque d'ADNC. Ces complexes peuvent etre utilises sous forme de vaccin pour provoquer des reponses immunitaires specifiques contre des cellules cancereuses ou preneoplasiques ou pour traiter ou prevenir le cancer.

L50 ANSWER 63 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1999002701 PCTFULL ED 20020515
TITLE (ENGLISH): PAK KINASE GENES AND POLYPEPTIDES AND METHODS OF USE
THEREOF
TITLE (FRENCH): GENES ET POLYPEPTIDES DE KINASES PAK, ET LEURS PROCEDES
D'UTILISATION
INVENTOR(S): FIELD, Jeffrey;
TANG, Yi;
CHEN, Zunxuan;
CHERNOFF, Jonathan;
GIBBS, Jackson, B.
PATENT ASSIGNEE(S): MERCK & CO., INC.;
UNIVERSITY OF PENNSYLVANIA;
FOX CHASE CANCER CENTER;
FIELD, Jeffrey;
TANG, Yi;
CHEN, Zunxuan;
CHERNOFF, Jonathan;
GIBBS, Jackson, B.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9902701	A1	19990121

DESIGNATED STATES

W: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID
IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ
PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US14412 A 19980710
PRIORITY INFO.: US 1997-60/052,242 19970711

ABEN The invention is generally directed to the construction of Pak kinase genes, and to polypeptides encoded by such genes. More specifically, the invention relates to isolated nucleic

acid molecules encoding Pak kinase polypeptides wherein the Pak kinases contain a kinase domain and wherein the Pak kinase polypeptides are substantially catalytically inactive, including but not limited to Pak kinase mutants such as the Pak1 kinase mutants Pak1R299, Pak1L83,L86 and Pak1L83,L86, R299. The invention also concerns polypeptides encoded by these isolated nucleic acid molecules and antibodies that specifically bind to these polypeptides. The invention also relates to methods of inhibiting animal cell transformation (particularly that mediated through the activity of the Ras oncogene), and to methods of treating or preventing physical disorders, including cancers and neurological disorders such as neurofibromatosis, in animals (particularly humans) using the mutant Pak kinase genes of the invention. The invention also relates to methods of identifying compounds that modulate the activity of Pak kinases, and to methods of identifying novel Pak kinase targets.

ABFR L'invention concerne generalement la construction de genes de kinases Pak et des polypeptides codes par lesdits genes. Elle se rapporte, plus specifiquement, a des molecules d'acide nucleique isolees codant les polypeptides de kinases Pak, les kinases Pak contenant un domaine kinase et les polypeptides de kinase Pak etant sensiblement inactifs du point de vue catalytique, lesdites molecules pouvant etre, entre autres, les mutants de kinase Pak1 comme Pak1R299, Pak1L83,L86 et Pak1L83,L86,R299. L'invention porte encore sur des polypeptides codes par ces molecules d'acide nucleique isolees et sur des anticorps qui se lient specifiquement a ces polypeptides. Elle concerne aussi des procedes d'inhibition de la transformation cellulaire animale (notamment celle induite par l'activite de l'oncogene Ras), et sur des procedes de traitement ou de prevention de troubles physiques, dont les cancers et les troubles neurologiques comme la neurofibromatose, chez les animaux (en particulier les humains), au moyen des genes mutants des kinases Pak. Elle se rapporte enfin a des procedes d'identification de composes qui modulent l'activite des kinases Pak et a des procedes d'identification de nouvelles cibles des kinases Pak.

L50 ANSWER 64 OF 79 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 953633 EUROPATFULL EW 199944 FS OS
TITLE: Cell culturing method and medium for producing proliferated, normal, differentiated human liver cells. Zellkulturverfahren und Medium zur Herstellung von vermehrungsfähige, normale, differenzierte Humane Leberzellen.
Procede de culture cellulaire et milieu pour la **production** des cellules de foie normales, aptes a proliferer et differenciees.
INVENTOR(S): Curcio, Francesco, Via Dei Castagni 35/1, 33010 Pagnacco, IT;
Coon, Hayden G., HC 75, Box 234A, East Sebago, Maine 04029, US;
Ambesi-Impiombato, Francesco Saverio, via Divisione Julia, 30, 33100 Udine, IT

PATENT ASSIGNEE(S): Livercell L.L.C., HC 75, Box 234A, East Sebago, Maine 04029, US
PATENT ASSIGNEE NO: 2767960
AGENT: Knott, Stephen Gilbert et al., MATHISEN, MACARA & CO.
The Coach House 6-8 Swakeleys Road, Ickenham Uxbridge UB10 8BZ, GB
AGENT NUMBER: 32681
OTHER SOURCE: ESP1999080 EP 0953633 A1 991103
SOURCE: Wila-EPZ-1999-H44-T1a
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO. PUB. TYPE: EPA1 EUROPÄISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND	DATE
'OFFENLEGUNGS' DATE:	EP 953633	A1	19991103
APPLICATION INFO.:	EP 1999-303337		19990428
PRIORITY APPLN. INFO.:	US 1998-66897		19980428

L50 ANSWER 65 OF 79 USPATFULL
ACCESSION NUMBER: 1998:157191 USPATFULL
TITLE: **Cell cultures** of and cells
culturing method for nontransformed parotid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849584		19981215
APPLICATION INFO.:	US 1995-485650		19950607 (8)
RELATED APPLN. INFO.:			Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lankford, Jr., Leon B.		
ASSISTANT EXAMINER:	Tate, Christopher R.		
LEGAL REPRESENTATIVE:	Bundock, John P.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1832		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed **cell culture** comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned **cell culture**, medium and conditioned medium designed for the culturing of parotid cells and other glandular cells such as pancreatic, thyroid, and parathyroid, and cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test

for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells. The nontransformed cells are cultured in a growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, and serum.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 66 OF 79 USPATFULL
ACCESSION NUMBER: 1998:82596 USPATFULL
TITLE: Method of altering blood sugar levels using non-transformed human pancreatic cells that have been expanded in culture
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
 Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
 Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780299		19980714
APPLICATION INFO.:	US 1995-480027		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lankford, Jr., Leon B.		
ASSISTANT EXAMINER:	Tate, Christopher R.		
LEGAL REPRESENTATIVE:	Bundock, John P.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1828		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed **cell culture** comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned **cell culture**, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 67 OF 79 USPATFULL
ACCESSION NUMBER: 1998:14903 USPATFULL
TITLE: Peptide inhibitors of tax-dependent transcription
INVENTOR(S): Matthews, Maura-Ann H., Boulder, CO, United States
 Stetler, Gary L., Boulder, CO, United States
 Anthony-Cahill, Spencer J., Boulder, CO, United States
 Anderson, David C., San Bruno, CA, United States
PATENT ASSIGNEE(S): Somatogen, Inc., Boulder, CO, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5717058 19980210
APPLICATION INFO.: US 1994-199508 19940218 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-21536, filed
on 23 Feb 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: LeGuyader, John L.
LEGAL REPRESENTATIVE: Nowak, Henry P., Novelli, Marianne F., Brown, Theresa
A.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 3494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to regulators of cellular gene transcription, particularly inhibitors of cellular gene transactivating factors and in particular to inhibition of gene transcription in a viral host cell that is subject to regulation by proteins or factors that originate from a virus as well as conjugates or fusion products of the inhibitors and internalization molecules, pharmaceutical compositions that can be used to alleviate or prevent the manifestation of disease states that are the result of unregulated DNA transcription as a result of transactivation, methods of treating diseases that are caused or exacerbated by the presence of transactivating factors, and regulated gene therapy to achieve long term drug delivery of the inhibitors of the present invention. This invention can be applied both to cells with genetic abnormalities or to cells infected with a virus. Preferably, at least one protein of the protein-protein interactions is a transactivating factor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 68 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1998050406 PCTFULL ED 20020514
TITLE (ENGLISH): CELL PROLIFERATION RELATED GENES
TITLE (FRENCH): GENES ASSOCIES A LA PROLIFERATION CELLULAIRE
INVENTOR(S): ZERVOS, Antonis, S.
PATENT ASSIGNEE(S): THE GENERAL HOSPITAL CORPORATION;
ZERVOS, Antonis, S.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9850406	A1	19981112

DESIGNATED STATES
W: AU CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE

APPLICATION INFO.: WO 1998-US9453 A 19980508
PRIORITY INFO.: US 1997-60/046,077 19970509

ABEN The present invention relates to three novel cancer related genes, Nmi, Omi and Rim. The Nmi gene encodes a myc gene product-binding protein. The Omi gene encodes a mammalian serine protease comprising an amino terminal regulatory domain, which includes a signal peptidase site, a triple repeat motif, an SH3 binding domain, and a consensus Mxi2/p38 kinase phosphorylation site, and a carboxy terminus serine protease catalytic domain. The retinoblastoma-interacting myosin-like gene (Rim gene) encodes a retinoblastoma binding protein comprising two leucine zipper structures, an RB family binding motif, an E1A / CtBP binding motif, and four nuclear localization sequences. Described herein are isolated and antisense nucleic acids molecules,

recombinant **expression** vectors, host cells and non-human transgenic animals containing an insertion or a disruption of the Nmi, Omi and Rim genes. Diagnostic, screening and therapeutic methods utilizing the compositions of the invention are also provided.

ABFR La presente invention concerne trois nouveaux genes associes au cancer, Nmi, Omi, et Rim. Le gene Nmi code une proteine de fixation au produit genique myc, le gene Omi code une proteine de serine protease mammifere renfermant un domaine regulateur amine terminal, lequel comprend un site peptidase signal, un motif a triple repetition, un domaine de fixation SH3, un site consensus de phosphorylation de Mxi2/p38 kinase, et un domaine catalytique de serine protease a terminaison carboxy. Le gene appartenant a la myosine en interaction avec le retinoblastome (ou gene Rim) code une proteine de fixation au retinoblastome, laquelle comprend deux structures de glissiere a leucine, un motif de fixation de la famille RB, un motif de fixation aux fragments E1A/CtBP, et quatre sequences de localisation nucleaire. L'invention concerne egalement des molecules d'acide nucleique isolees et antisens, des vecteurs d'**expression** recombinants, des cellules hotes et des animaux transgeniques contenant une insertion ou une rupture desdits genes Nmi, Omi, et Rim. L'invention concerne enfin des methodes diagnostique, therapeutique et de criblage utilisant les compositions de cette invention.

L50 ANSWER 69 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1998022588 PCTFULL ED 20020514
TITLE (ENGLISH): AN IMPROVED METHOD FOR THE **PRODUCTION** AND
PURIFICATION OF ADENOVIRAL VECTORS
TITLE (FRENCH): PROCEDE AMELIORE POUR **PRODUCTION** ET
PURIFICATION DE VECTEURS D'ADENOVIRUS
INVENTOR(S): ZHANG, Shuyuan;
THWIN, Capucine;
WU, Zheng;
CHO, Toohyon
PATENT ASSIGNEE(S): INTROGEN THERAPEUTICS, INC.;
ZHANG, Shuyuan;
THWIN, Capucine;
WU, Zheng;
CHO, Toohyon
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9822588	A2	19980528

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TT UA UG US UZ VN YU ZW GH KE LS
MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE
DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US21504 A 19971120
PRIORITY INFO.: US 1996-60/031,329 19961120
ABEN The present invention addresses the need to improve the yields of viral vectors when grown in

cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached **cell culture** system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 **production** with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the

increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.

ABFR L'invention se rapporte a la necessite d'améliorer les rendements de vecteurs viraux obtenus par des procédés de culture cellulaire. Il a été démontré en particulier que pour les adenovirus, l'utilisation de vitesses de perfusion faibles à moyennes dans un système de culture cellulaire fixe permettait d'assurer un meilleur rendement. Dans d'autres modes de réalisation, les inventeurs ont démontré une **production** améliorée d'Ad-p53 avec des cellules cultivées dans un milieu sans serum, et en particulier dans une culture en suspension sans serum. L'utilisation d'une lyse par détergents constitue également un facteur important dans l'accroissement des rendements. Lorsque les aspects de l'invention sont combinés les virus peuvent être purifiés en une seule étape chromatographique, ce qui permet d'obtenir des virus purifiés ayant la même qualité que des préparations formées à partir de double bandage CsCl au moyen d'une ultracentrifugeuse.

L50 ANSWER 70 OF 79 USPATFULL

ACCESSION NUMBER: 97:59097 USPATFULL
TITLE: Method for preparing an expanded culture and clonal strains of pancreatic, thyroid or parathyroid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures, Inc., Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646035		19970708
APPLICATION INFO.:	US 1995-480149		19950607 (8)
RELATED APPLN. INFO.:			Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rollins, John W.
ASSISTANT EXAMINER: Larson, Kristin
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1831
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed **cell culture** comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating

the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned **cell culture**, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 71 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1997040183 PCTFULL ED 20020514
TITLE (ENGLISH): ARTIFICIAL CHROMOSOMES, USES THEREOF AND METHODS FOR
PREPARING ARTIFICIAL CHROMOSOMES
TITLE (FRENCH): CHROMOSOMES ARTIFICIELS, LEURS UTILISATIONS ET LEURS
PROCEDES DE PREPARATION
INVENTOR(S): HADLACZKY, Gyula;
SZALAY, Aladar, A.
PATENT ASSIGNEE(S): THE BIOLOGICAL RESEARCH CENTER OF THE HUNGARIAN ACADEMY
OF SCIENCES;
LOMA LINDA UNIVERSITY;
AMERICAN GENE THERAPY, INC.;
HADLACZKY, Gyula;
SZALAY, Aladar, A.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9740183	A2	19971030

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ
UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR
GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
MR NE SN TD TG

APPLICATION INFO.: WO 1997-US5911 A 19970410
PRIORITY INFO.: US 1996-629,822 19960410
US 1996-682,080 19960715
US 1996-695,191 19960807

ABEN Methods for preparing cell lines that contain artificial chromosomes, methods for preparation of artificial chromosomes, methods for purification of artificial chromosomes, methods for targeted insertion of heterologous DNA into artificial chromosomes, and methods for delivery of the chromosomes to selected cells and tissues are provided. Also provided are cell lines for use in the methods, and cell lines and chromosomes produced by the methods. In particular, satellite artificial chromosomes that, except for inserted heterologous DNA, are substantially composed of heterochromatin, are provided. Methods for use of the artificial chromosomes, including for gene therapy, **production** of gene products and **production** of transgenic plants and animals are also provided.

ABFR L'invention concerne des methodes de preparation de lignees cellulaires

qui contiennent des chromosomes artificiels, leurs procedes de preparation et de purification, des procedes d'insertion ciblee d'ADN heterologue dans lesdits chromosomes artificiels et des procedes de liberation desdits chromosomes dans des cellules et tissus selectionnes. Elle porte aussi sur des lignees cellulaires a utiliser dans lesdits procedes, ainsi que sur des lignees cellulaires et des chromosomes produits selon lesdits procedes. On decrit, en particulier, des chromosomes artificiels satellites qui, a l'exception de l'ADN heterologue insere, se composent sensiblement d'heterochromatine. Des procedes d'utilisation des chromosomes artificiels, dont la therapie genique, la **production** de produits geniques et la **production** de plantes et d'animaux transgeniques sont egalement decrits.

L50 ANSWER 72 OF 79 PCTFULL COPYRIGHT 2003 Univentio
 ACCESSION NUMBER: 1996040857 PCTFULL ED 20020514
 TITLE (ENGLISH): METHODS AND DEVICES FOR THE REMOVAL OF PSORALENS FROM BLOOD PRODUCTS
 TITLE (FRENCH): PROCEDES ET DISPOSITIF POUR L'EXTRACTION DES PSORALENES DES PRODUITS SANGUINS
 INVENTOR(S): HEI, Derek, J.
 PATENT ASSIGNEE(S): STERITECH, INC.; HEI, Derek, J.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9640857	A1	19961219

DESIGNATED STATES
 W: AU CA JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC
 NL PT SE

APPLICATION INFO.: WO 1996-US9846 A 19960607
 PRIORITY INFO.: US 1995-8/484,926 19950607
 US 1996-8/659,249 19960607
 US 1996-8/660,908 19960607

ABEN Methods and devices for the removal of psoralens and psoralen photoproducts from blood products are described. The methods include contacting a psoralen- and irradiation-treated blood product with a resin capable of adsorbing psoralens and psoralen photoproducts. The removal process is particularly suitable for use with platelet concentrates and plasma because the process does not have a significant adverse effect on clotting factor function. The methods and devices can be incorporated with apheresis systems and other devices and procedures currently used to process blood products for transfusion.

ABFR Procedes et dispositifs d'extraction des psoralenes et des photoproduits crees par les psoralenes dans les produits sanguins. Le procede consiste a mettre un produit sanguin traite par psoralenes et irradiation en contact avec une resine capable d'adsorption des psoralenes et des photoproduits crees par les psoralenes. Le processus d'extraction est particulierement adapte a l'utilisation avec des concentres de plaquettes et du plasma, dans la mesure ou le procede n'a pas d'effet indesirable notable sur la fonction du facteur de coagulation. Les procedes et dispositifs

descripts peuvent etre integres a des systemes d'apherese et dans d'autres dispositifs et procedes actuellement utilises pour traiter les produits sanguins pour la transfusion.

L50 ANSWER 73 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1996008965 PCTFULL ED 20020514
TITLE (ENGLISH): PHOTODYNAMIC INACTIVATION OF VIRAL AND BACTERIAL BLOOD
CONTAMINANTS WITH HALOGENATED COUMARIN AND FUROCOUMARIN
SENSITIZERS
TITLE (FRENCH): PROCEDE D'INACTIVATION PHOTODYNAMIQUE DE CONTAMINANTS
DU SANG DE NATURE VIRALE ET BACTERIENNE A L'AIDE DE
SENSIBILISANTS A LA COUMARINE OU LA FUROCOUMARINE
INVENTOR(S): PARK, Sang, Chul;
GOODRICH, Raymond, P., Jr.;
YERRAM, Nagender;
SOWEMINO-COKER, Samuel, O.;
PLATZ, Matthew, S.;
AQUILA, Brian
PATENT ASSIGNEE(S): CRYOPHARM CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9608965	A1	19960328
------------	----	----------

DESIGNATED STATES

W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE
HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN
KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:

WO 1995-US12069	A	19950921
US 1994-8/311,125		19940922
US 1994-8/343,680		19941122
US 1995-8/427,080		19950421
US 1995-8/461,626		19950705

PRIORITY INFO.:

ABEN Viral, bacterial and parasitic contaminants in biological compositions are photodynamically inactivated by mixing halogenated coumarin and furocoumarin photosensitizers with the biological composition and irradiating the mixture. The figure depicts the proposed energy diagram of the instant photosensitizers.

ABFR Ont peut inactiver de maniere photodynamique les contaminants de nature virale, bacterienne ou parasitaire presents dans des compositions biologiques en melangeant auxdites compositions des photosensibilisants halogenes de coumarine et de furocoumarine, puis en irradiant le melange. La figure 1 represente le schema energetique propose des photosensibilisants a action instantanee.

L50 ANSWER 74 OF 79 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1994023572 PCTFULL ED 20020513
TITLE (ENGLISH): CELL CULTURING METHOD AND MEDIUM
TITLE (FRENCH): PROCEDE ET MILIEU DE CULTURE DE CELLULES
INVENTOR(S): COON, Hayden, G.;
AMBESI-IMPIOMBATO, Francesco, Saverio;
CURCIO, Francesco
PATENT ASSIGNEE(S): HUMAN CELL CULTURES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9423572

A1 19941027

DESIGNATED STATES

W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
SE

APPLICATION INFO.: WO 1994-US3101

A 19940321

PRIORITY INFO.: US 1993-44,010

19930408

US 1993-83,772

19930630

ABEN The present invention provides a method for producing an expanded non-transformed **cell culture** comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned **cell culture**, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

ABFR La presente invention concerne un procede pour produire une culture croissante de cellules non transformees consistant a: (1) preparer un broyat de tissu partiellement purifie; (2) concentrer les cellules resultantes et les morceaux de tissu; (3) remettre en suspension les cellules et les morceaux de tissu concentres dans un milieu de culture capable d'entretenir la division cellulaire, contenu dans un recipient de culture; (4) incuber les cellules; et (5) repiquer periodiquement les cultures. La presente invention concerne les autres souches clonales de cellules produites par le procede de culture en question, le milieu et le milieu conditionne pour la culture de telles cellules, en particulier les cellules pancréatiques, thyroïdiennes, parathyroïdiennes, et de la glande parotide, et l'utilisation de cellules pancréatiques de culture pour former des pseudo-tissus pancréatiques composés de cellules individuelles ou formant des agregats (pseudo-ilots) tenus par une matrice, pour traiter dereglements de la proportion de sucre dans le sang chez les mammifères et pour effectuer des tests de cytotoxicite et d'activite auto-immune concernant les cellules endocrines pancréatiques.

L50 ANSWER 75 OF 79 PCTFULL COPYRIGHT 2003 Univentio

ACCESSION NUMBER: 1994019473 PCTFULL ED 20020513

TITLE (ENGLISH): MODULATORS OF GENE **EXPRESSION**

TITLE (FRENCH): MODULATEURS DE L'**EXPRESSION** GENIQUE

INVENTOR(S): MATTHEWS, Maura-Ann, H.;

STETLER, Gary, L.;

ANTHONY-CAHILL, Spencer, J.;

ANDERSON, David, C.

PATENT ASSIGNEE(S): SOMATOGEN, INC.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE:
PATENT INFORMATION:

Patent

NUMBER	KIND	DATE
WO 9419473	A1	19940901

DESIGNATED STATES

W:

AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP
KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU
SD SE SK TJ UA UZ VN AT BE CH DE DK ES FR GB GR IE IT
LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD
TG

APPLICATION INFO.:

WO 1994-IB20 A 19940223

PRIORITY INFO.:

US 1993-8/021,536 19930223

ABEN The present invention relates to regulators of cellular gene transcription, particularly inhibitors of cellular gene transactivating factors and in particular to inhibition of gene transcription in a viral host cell that is subject to regulation by proteins or factors that originate from a virus as well as conjugates or fusion products of the inhibitors and internalization molecules, pharmaceutical compositions that can be used to alleviate or prevent the manifestation of disease states that are the result of unregulated DNA transcription as a result of transactivation, methods of treating diseases that are caused or exacerbated by the presence of transactivating factors, and regulated gene therapy to achieve long term drug delivery of the inhibitors of the present invention. This invention can be applied both to cells with genetic abnormalities or to cells infected with a virus. Preferably, at least one protein of the protein-protein interactions is a transactivating factor.

ABFR Regulateurs de la transcription genique cellulaire. Il s'agit plus particulierement d'inhibiteurs de facteurs de transactivation genique cellulaire, et notamment de l'inhibition de la transcription genique dans une cellule hote virale soumise a la regulation par des proteines ou facteurs originaires d'un virus, ainsi que des conjugues ou produits de fusion des inhibiteurs et des molecules d'internalisation; de compositions pharmaceutiques utilisables pour soulager ou empêcher la manifestation d'etats pathologiques dus a la transcription non regulee d'ADN provoquée par la transactivation; de procedes de traitement de maladies provoquées ou exacerbées par la presence de facteurs de transactivation; et d'une therapie genique regulee permettant une administration a long terme des inhibiteurs precites. L'invention s'applique a la fois aux cellules presentant des anomalies genetiques et aux cellules infectees par un virus. De preference, au moins une proteine des interactions proteine-proteine est un facteur de transactivation.

L50 ANSWER 76 OF 79 USPATFULL

ACCESSION NUMBER: 92:38165 USPATFULL

TITLE: Acidic formulations of t-PA

INVENTOR(S): Johnston, Michael D., Beckenham, England

Berger, Henry, Cary, NC, United States

PATENT ASSIGNEE(S): Burroughs Wellcome Co., Research Triangle Park, NC,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5112609		19920512
APPLICATION INFO.:	US 1990-527634		19900521 (7)
DISCLAIMER DATE:	20071106		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1986-862774, filed on 13 May 1986, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-1358	19850528
	GB 1985-21704	19850831
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Stone, Jacqueline	
LEGAL REPRESENTATIVE:	Brown, Donald, Nielsen, Lawrence A.	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	497	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	An aqueous parenteral solution of tissue-plasminogen activator, in which the pH is from 2 to 5.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 77 OF 79	PCTFULL	COPYRIGHT 2003 Univentio
ACCESSION NUMBER:	1992011864	PCTFULL ED 20020513
TITLE (ENGLISH):	METHOD OF DETECTING CIRCULATING ANTIBODY TYPES USING DRIED OR LYOPHILIZED CELLS OR CELL-LIKE MATERIAL	
TITLE (FRENCH):	PROCEDE DE DETECTION DE TYPES ANTICORPAUX EN CIRCULATION A L'AIDE DE CELLULES OU MATIERES CELLULAIRES SECHEES OU LYOPHILISEES	
INVENTOR(S):	HACKETT, Roger, W.; GOODRICH, Raymond, P., Jr.; WILLIAMS, Christine, M.; OLSON, Jon, A.; CHO, Miller; GALLE, Richard, F.	
PATENT ASSIGNEE(S):	CRYOPHARM CORPORATION; HACKETT, Roger, W.; GOODRICH, Raymond, P., Jr.; WILLIAMS, Christine, M.; OLSON, Jon, A.; CHO, Miller; GALLE, Richard, F.	

LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 9211864	A1	19920723

DESIGNATED STATES	AT AU BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE US
W:	US US
APPLICATION INFO.:	WO 1992-US63 A 19920110
PRIORITY INFO.:	US 1991-639,937 19910111
	US 1991-695,169 19910503
	US 1991-786,109 19911101

ABEN A method is provided for qualitatively detecting in vitro the presence or absence of selected circulating antibody types using a diagnostic kit comprising reconstituted, after lyophilization or evaporative drying, red blood cell samples or other cell or cell-like material which have antigens

which are recognized and bound by the selected antidoby-type to be screened. Diagnostic kits containing the lyophilized blood samples according to the present invention have improved shelf life, and may comprise lyophilized samples packaged in a variety of forms convenient for manual single-test uses or automated multiple-test uses.

ABFR Procede de detection qualitative in vitro de la presence ou de l'absence de certains types anticorpaux en circulation a l'aide d'un necessaire de diagnostic qui comporte des echantillons d'erythrocytes ou d'autres matieres cellulaires reconstitues apres la lyophilisation et le sechage par evaporation et dotes d'antigenes reconnus et lies par le type anticorpal selectionne a depister. Les necessaires de diagnostic qui contiennent ces echantillons sanguins lyophilises presentent une duree de conservation plus longue et peuvent comporter des echantillons lyophilises conditionnes sous diverses formes adaptees aux essais manuels uniques ou aux essais multiples automatises.

L50 ANSWER 78 OF 79 USPATFULL
ACCESSION NUMBER: 90:85554 USPATFULL
TITLE: Solid hydrochloride salt of t-PA
INVENTOR(S): Johnston, Michael D., Beckenham, England
Berger, Henry, Cary, NC, United States
PATENT ASSIGNEE(S): Burroughs Wellcome Co., Research Triangle Park, NC,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4968617		19901106
APPLICATION INFO.:	US 1988-226422		19880729 (7)
DISCLAIMER DATE:	20070529		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-13358	19850528
	GB 1985-21705	19850831
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Stone, Jacqueline	
LEGAL REPRESENTATIVE:	Brown, Donald	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	453	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A lyophilised pharmaceutical formulation of tissue plasminogen activator and a process for its preparation by vacuum drying a frozen aqueous solution of thereof, in which the pH is from 2 to 5.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 79 OF 79 USPATFULL
ACCESSION NUMBER: 90:42340 USPATFULL
TITLE: Low pH pharmaceutical formulation containing t-PA
INVENTOR(S): Johnston, Michael D., Beckenham, England
Berger, Henry, Cary, NC, United States
PATENT ASSIGNEE(S): Burroughs Wellcome Co., Research Triangle Park, NC,
United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 4929444 19900529
APPLICATION INFO.: US 1986-862817 19860513 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-13358	19850528
	GB 1985-21705	19850831
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Stone, Jacqueline M.	
LEGAL REPRESENTATIVE:	Brown, Donald	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	498	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A lyophilized pharmaceutical formulation of tissue plasminogen activator and a process for its preparation by vacuum drying a frozen aqueous solution of thereof, in which the pH is from 2 to 5.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>